Patent Grant
9950035
The present technology relates to methods of treating inflammatory disorders, including osteoarthritis. In particular, methods comprise use of solutions comprising cytokines, including non-immunogenic solutions derived from blood and other tissues.
Inflammation is a complex cellular and biochemical process that occurs in the affected blood vessels and adjacent tissues in response to an injury or abnormal stimulation caused by a physical, chemical, or biologic agent, such as a pathogen, allergen or irritant. The inflammatory process includes local reactions and resulting morphologic changes in tissue; the destruction or removal of the causative agent; and the responses that lead to repair and healing. In most instances, inflammation is a beneficial and transient process, which subsides as the body attacks and overcomes an infectious or other harmful agent. However, in some instances, inflammation can be chronic self-perpetuating process, for example, as part of an ongoing degenerative process (such as arthritis) or autoimmune disease, leading to destruction of tissue. Chronic inflammation is associated with a variety of disorders, including rheumatoid arthritis, atherosclerosis, ischemic heart disease, periodontitis, colitis, and some cancers.
An inflammatory response consists of a cascade of biochemical events, involving the local vascular system and immune system, and various cells within the injured tissue. The process involves the release of numerous cell-derived mediators, including histamine, interferon-gamma, interleukin-8, leukotriene, nitric oxide, prostaglandins, tumor necrosis factor-alpha, and interleukin-1. In particular, interleukin-1 (IL-1) includes a family of cytokines that can stimulate lymphocytes and macrophages, activate phagocytes, increase prostaglandin production, contribute to degeneration of bone joints, increase bone marrow cell proliferation, and are involved in many chronic inflammatory conditions. IL-1 can be generated by macrophages, monocytes, and dendritic cells, and can be part of the inflammatory response against infection.
The mode of action of IL-1 can be mediated by interleukin-1 receptor antagonist protein (IL-1ra; also known as “IRAP”). IL-1ra binds to the same receptor on the cell surface as IL-1, and thus prevents IL-1 from sending a signal to that cell. IL-1ra is secreted from white blood cells, including monocytes, macrophages, neutrophils, polymorphonuclear cells (PMNs), and other cells, and can modulate a variety of IL-1 related immune and inflammatory responses, as described by Arend W P, Malyak M, Guthridge C J, Gabay C (1998) “Interleukin-1 receptor antagonist: role in biology” Annu. Rev. Immunol. 16: 27-55. Production of IL-1ra is stimulated by several substances including adherent immunoglobulin G (IgG), other cytokines, and bacterial or viral components. IL-1ra, as well as other cytokines such as soluble tumor necrosis factor receptor 1 (sTNF-R1), soluble tumor necrosis factor receptor 2 (sTNF-R2) and (soluble interleukin receptor 1 (sIL-1RII), is an important natural anti-inflammatory protein in arthritis, colitis, and granulomatous pulmonary disease.
IL-1ra can be used in the treatment of rheumatoid arthritis, an autoimmune disease in which IL-1 plays a key role, reducing inflammation and cartilage degradation associated with the disease. For example, Kineret™ (anakinra) is a recombinant, non-glycosylated form of IL-1ra (Amgen Manufacturing, Ltd., Thousand Oaks, Calif.). Various recombinant interleukin-1 inhibitors and methods of treatment are described in U.S. Pat. No. 6,599,873, Sommer et al., issued Jul. 29, 2003; U.S. Pat. No. 5,075,222, Hannum et al., issued Dec. 24, 1991; and U.S. Application Publication No. 2005/0197293, Mellis et al., published Sep. 8, 2005 In addition, methods for producing IL-1ra from body fluids, including the use of autologous fluids, are described in U.S. Pat. No. 6,623,472, Reinecke et al., issued Sep. 23, 2003; U.S. Pat. No. 6,713,246, Reinecke et al., issued Mar. 30, 2004; and U.S. Pat. No. 6,759,188, Reinecke et al., issued Jul. 6, 2004.
Many such treatments for inflammation are known in the art. Therapies known in the art may be directed to removal of the underlying irritant or agent causing the inflammatory reaction, or by mediating one or more aspects of the inflammatory response. Examples include glucocorticoid steroids (such as hydrocortisone, cortisone, prednisone, and beclomethasone), non-steroidal anti-inflammatory drugs (such as aspirin, ibuprofen and naproxen), and immune selective anti-inflammatories. However, many such treatments present side effects, particularly during chronic administration, or have pharmacologic characteristics that limit their use. For example, while compositions and methods using IL-1ra are known in the art, they may be associated with issues regarding stability and half-life of IL-1ra as well as the amount and rate of IL-1ra provided. Moreover, many treatments do nothing to address the underlying causes of the inflammatory process. Accordingly, improved methods of treating inflammation are needed, offering one or more of improved efficacy, reduced side effects, and improved dosing characteristics.
The present technology provides methods for generating solutions rich in anti-inflammatory cytokines for use in treatment of inflammation and other disorders mediated by interleukin-1 and tumor necrosis factor-alpha. Methods for generating such solutions include contacting a liquid volume of cytokine-producing cells (e.g., white blood cells) with a solid extraction material, removing the solid extraction material from the liquid. Such methods further comprise one or both of removing the cells from the liquid during or after contacting the liquid with the solid extraction material, and freeze drying (lyophilizing) the solution after the solid extraction material is removed from the liquid. In some embodiments, the liquid volume of cells is obtained from a plurality of mammalian subjects. Compositions of this technology are non-immunogenic, allowing their use in treating mammalian subjects regardless of the source of the cells used in making the solution.
In particular, the present technology provides method for making a non-immunogenic anti-inflammatory cytokine composition, including processes comprising:
In other embodiments, methods comprise:
In various embodiments, the liquid comprising cytokine-producing cells may comprise whole blood, bone marrow aspirate, adipose tissue, urine, fractions thereof (such as platelet-rich plasma, and bone marrow concentrate), and mixtures thereof, containing (for example) white blood cells, adipose stromal cells, adipocytes, and bone marrow stromal cells. The solid extraction material may be selected from the group consisting of corundum, quartz, titanium, dextran, agarose, polyacrylamide, polystyrene, polyethylene, polyvinyl chloride, polypropylene, and combinations thereof.
In some embodiments, the liquid comprising cytokine-producing cells is prepared by a process comprising:
In various embodiments, the obtaining and contacting steps comprise:
In various embodiments, the anti-inflammatory cytokine composition comprises
Methods of treating a condition mediated by interleukin-1 receptor, such as inflammation, in a human or other mammalian subject, comprising topical administration of a composition of the present technology. In various embodiments, the composition is made using a cytokine cell suspension obtained from a mammalian subject, or plurality of subjects, other than the subject to be treated.
Corresponding reference numerals indicate corresponding parts throughout the several views of the drawings. It should be noted that the figures set forth herein are intended to exemplify the general characteristics of materials, compositions, devices, and methods among those of the present technology, for the purpose of the description of certain embodiments. These figures may not precisely reflect the characteristics of any given embodiment, and are not necessarily intended to fully define or limit specific embodiments within the scope of this technology.
The following description of technology is merely exemplary in nature of the composition, manufacture and use of one or more inventions, and is not intended to limit the scope, application, or uses of any specific invention claimed in this application or in such other applications as may be filed claiming priority to this application, or patents issuing therefrom. A non-limiting discussion of terms and phrases intended to aid understanding of the present technology is provided at the end of this Detailed Description.
The present technology relates to compositions, methods of making compositions, and methods of using compositions for the treatment of inflammatory disorders, and other disorders mediated by interleukin-1. In general, such compositions are made by a process comprising:
The present technology provides methods for treating inflammatory disorders other disorders mediated by interleukin-1 in humans or other mammalian subjects using compositions (herein referred to as “Protein Solutions”) comprising proteins dissolved, suspended or otherwise carried for delivery to a mammalian subject in a physiologically-acceptable medium. In various embodiments, such compositions comprise proteins (e.g., cytokines) that are native to whole blood in normal mammal subjects. Such compositions may also contain viable cells, including platelets, white blood cells, and combinations thereof.
In various embodiments, the Protein Solution comprises at least two proteins selected from the group consisting of IL-1ra, sTNF-RI, sTNF-RII (soluble tumor necrosis factor-receptor 2), IGF-I (insulin-like growth factor 1), EGF (epidermal growth factor), HGF (hepatocyte growth factor), PDGF-AB (platelet-derived growth factor AB), PDGF-BB (platelet-derived growth factor BB), VEGF (vascular endothelial growth factor), TGF-β1 (transforming growth factor-β1, and sIL-1RII (soluble interleukin receptor II), wherein the concentration of each of the two proteins in the composition is greater than the concentration of each protein in normal blood. For the sake of clarity, the Protein Solution may contain three or more of the proteins from the recited group. While the concentration of every such protein in the composition may be greater than its respective concentrations in in normal blood, it is not necessary that the concentration of more than two of the proteins be greater than their respective concentrations in normal blood.
In various embodiments, a Protein Solution comprises the following components.
Protein concentrations can be measured using the methods set forth in Example 4.
The composition further preferably comprises viable white blood cells, lysed white blood cells, or both. In a preferred composition, the Protein Solution comprises monocytes, granulocytes, and platelets. In various embodiments, a Protein Solution comprises the following components.
It will be understood that this concentration is species specific. Further, it is understood that concentrations may vary among individual subjects. Thus, in methods comprising production of a Protein Solution from the blood or other tissue containing cytokine-producing cells, the concentration of proteins and cells in the Protein Solution may vary from those recited above; the values recited above are mean values for concentrations as may be seen in a population of subjects.
In various embodiments, the concentration of one or more of the proteins or other components in the Protein Solution is greater than the concentration of the component in normal blood. (Compositions with such higher concentrations of components are said to be “rich” in such components.) As referred to herein, the concentration of a component in “normal” blood or other tissue is the concentration found in the general population of mammalian subjects from which the tissue is obtained, e.g., in normal whole blood. In methods wherein the anti-inflammatory cytokine composition is derived from tissue from a specific subject, the “normal” concentration of a protein or cell may be the concentration in the blood of that individual before processing is performed to derive the protein or cell.
Thus, in various embodiments, the concentration of one or more components of the Protein Solution is greater than about 1.5 times, about 2 times, or about 3 times, greater than the concentration of the component in normal blood. For example, components may have greater concentrations in the compositions, relative to normal (whole) blood, as follows:
For example, a Protein Solution may comprise:
In some embodiments, the concentration of IL-1ra in the Protein Solution is preferably at least 5,000, or at least 10,000, times greater than the concentration of interleukin-1α in the Protein Solution. The ratio of IL-1ra:interleukin-1β (IL-1β) concentrations is preferably at least 100. In some embodiments, the concentration of IL-1ra in the Protein Solution is preferably at least 1500, or at least 8000, times greater than the concentration of IL-1β in the Protein Solution. The ratio of sIL-1RII:interleukin-1β (IL-1β) concentrations is preferably greater than 1. In some embodiments, the sIL-1RII in the Protein Solution is preferably at least 2000, or at least 45000, times greater the concentration of interleukin-1β in the Protein Solution.
The present technology provides Protein Solutions wherein one or more components of the Protein Solution are obtained from non-autologous sources, such as through recombinant or synthetic methods, or by isolation from allogeneic sources (i.e., from subjects of the same species as the subject to whom the solution is to be administered) or xenogeneic sources (i.e., from animal sources other than the species to whom the solution is to be administered). In some embodiments, the Protein Solutions consists, or consists essentially, of such allogeneic components. However, in various embodiments, the Protein Solution additionally comprises one or more components (e.g., white blood cells and platelets) derived from the subject to whom the solution is to be administered in a treatment methods according to this technology. Such components are, accordingly, “autologous.” In some embodiments, the Protein Solution comprises mixtures of autologous and allogeneic components.
Protein Solutions may be made by any of a variety of methods, including admixture of individual components, and processes wherein one or more components are derived from a source material. In various embodiments, the Protein Solution is made by fractionating a cytokine cell suspension, to produce a protein solution comprising IL1-ra.
Obtaining Protein Solutions by Contacting Cytokine-Producing Cells with an Extraction Material
In various embodiments, Protein Solutions are made by derivation of one or more components from tissue comprising cytokine-producing cells. As referred to herein, a “cytokine producing tissue” is a tissue obtained from a mammalian subject, comprising cells that are capable of producing cytokines. Such cells include white blood cells, adipose stromal cells, bone marrow stromal cells, and combinations thereof. It is understood that white blood cells include monocytes, lymphocytes, and granulocytes such as neutrophils, eosinophils, and basophils. White blood cell useful in the methods of this technology preferably include monocytes and neutrophils. Cytokine producing tissues among those useful herein include blood, adipose tissue, bone marrow, and fractions thereof, as further discussed below.
Blood useful herein includes whole blood, plasma, platelet-rich plasma, platelet-poor plasma, and blot clots. In a preferred embodiment, methods of the present technology use platelet-rich plasma (PRP), containing white blood cells and platelets, comprising the buffy coat layer created by sedimentation of whole blood. Adipose tissue useful herein includes any fat tissue, including white and brown adipose tissue, which may be derived from subcutaneous, omental/visceral, mammary, gonadal, or other adipose tissue sites. Bone marrow useful herein includes red marrow and yellow marrow. In a preferred embodiment, bone marrow is bone marrow concentrate, obtained from the red marrow of long bones, comprising hematopoietic and mesenchymal stems cells. As discussed above, compositions of the present technology may be made from blood, adipose, and bone marrow tissue from allogeneic sources, relative to the subject to be treated according to methods of this technology. Compositions may also be made from combinations of allogeneic and autologous tissues.
In some embodiments, methods comprise fractionating a liquid (a “cytokine cell suspension.”) comprising cells capable of producing cytokines, such as IL1-ra and sTNF-R1. As discussed above, such cells include white blood cells, adipose stromal cells, bone marrow stromal cells, and combinations thereof. In some embodiments, the cytokine cell suspension is a liquid comprising white blood cells. It should be understood that the cytokine cell suspension comprises cells and an extra-cellular liquid, regardless of the relative proportions of the cells and liquid. In some embodiments, the suspension may comprise primarily cells, with liquid being present as only a minor component, essentially wetting the cells. In some embodiments, the liquid may comprise two phases, consisting of a phase primarily consisting of liquid and a phase primarily consisting of cells, forming a suspension of cells in the liquid only upon agitation or other mixing.
As exemplified in
In various embodiments, obtaining comprises isolating a cytokine cell suspension, comprising white blood cells or other cytokine-producing cells, from blood, adipose tissue, bone marrow aspirate or other tissue comprising cytokine-producing cells, as exemplified in Steps 110, 120 and 125 of
Obtaining a Cytokine Cell Suspension from Blood
In embodiments comprising the use of blood, the blood may be used directly in contacting the solid extraction material, as exemplified in step 140 of
In various embodiments, methods of the present technology comprise creating PRP as the cytokine cell suspension, using centrifugation. Such methods generally comprise placing blood in a container a separator operable to separate the blood into two or more fractions, and centrifuging the separator to create a platelet-rich plasma fraction. Such devices may include a tube and a buoy disposed in the tube, wherein the buoy has a density such that the buoy reaches an equilibrium position upon centrifugation of the tissue in the tube, the equilibrium position being between a first fraction and a second fraction comprising white blood cells, the second fraction having a concentration of white blood cells greater than the concentration of white blood cells in the first fraction. Such methods further comprise centrifuging the tube so that the buoy defines an interface between the first fraction and the second fraction comprising white blood cells. The second fraction is then collected for further use in the methods of this technology.
One such device useful herein is described in U.S. Pat. No. 7,992,725, Leach et al., issued Aug. 9, 2011. Such a device is commercially available as GPS III Platelet Concentrate and Separation System, from Biomet Biologics, LLC (Warsaw, Ind., USA). The device can be used in a clinical or laboratory environment to isolate fractions from a suspension or multi-component tissue material obtained from a subject, such as blood, bone marrow aspirate, cerebrospinal fluid, adipose tissue, Isolated fractions can include platelets, platelet poor plasma, platelet rich plasma and stromal cells. The isolated fractions can each have equilibrium point or positions within the separation container that are achieved when separation has occurred. For example, a buffy coat (PRP) of whole blood may have an equilibrium position above that of the red blood cells when a sample of whole blood is separated.
The fractionation device 200 is exemplified in
The buoy 210 is carried in the separation container 205 and has a tuned density that is configured to reach a selected equilibrium position in a suspension. The buoy can have its density tuned in the range from about 1.0 g/cc to about 1.10 g/cc, such as about 1.06 g/cc. The buoy 210, according to various embodiments, can be formed to include the tuned density and can be formed of one or more materials to achieve the tuned density.
Referring to
In some embodiments, the buoy 210 can comprise a collection port 240. The collection port 240 communicates with access port 245 and communicates with a collection space 220 above buoy upper surface 250 and can be located near the buoy perimeter 210a. In some embodiments, the collection port 240 is not carried on the buoy, but rather the collection port is a withdraw device such as a syringe that is inserted through an access port or top of the device 200.
According to various embodiments, an isolator 255, is coupled to the buoy 210. The combination of the isolator and buoy, according to various embodiments, can also be referred to as a separation assembly member. The isolator 255, for example, provides a means for creating the collection compartment 220 and comprises one or more spacers 260, 265 to position the isolator 255 apart from the buoy 210 to create the collection compartment 220. A withdraw port 270 can be carried on the isolator 255 communicating with the withdraw port 245 and the collection port 240. The spacer 260, 265 can also serve as a conduit 275 between the collection port 50 and a withdraw or withdraw port 245. The withdraw port 245 serves as a structure for withdrawing the isolated or middle fraction 225 from the collection compartment 220.
After centrifuging the device 200 containing whole blood, the first fraction or top fraction 230, can be platelet-poor-plasma, the middle fraction 225 can be platelet-rich plasma or platelet concentrate, and a bottom fraction 278 can be red blood cells. Therefore, the fractionation method further comprises withdrawing a desired fraction from the device 200. Various ports 205, 245 and 280 can be provided to allow access to any appropriate compartment of the device 200. The access ports 205, 245, 280 can be any means that allow communication from outside the separation device 200 to the device's interior, such as a Luer lock port, a septum, a valve, or other opening. Additionally, collection vent tube 285 allows removal of a fractionated suspension in the collection compartment 220 through opening 290 without the need to remove the fraction, such as plasma, above the isolator 255. Although, without a collection vent tube 285, the fraction above the isolator could be removed and the collection area could be vented to the area above the isolator.
A method for using the fractionation device 200 can begin by inputting whole blood via an access port 205. The fractionation device 200 is placed into a centrifuge and spun for a period that is appropriate for fractionating whole blood. An exemplary period can be for about five minutes to about twenty minutes at a rate of about 320 rpm to about 5000 rpm. This speed may produce a selected gravity that may be approximately 7.17×g to about 1750×g (times greater than the normal force of gravity).
Other devices that may be used to isolate platelet-rich plasma described, for example, in U.S. Pat. No. 5,585,007, Antanavich, issued Dec. 17, 1996; U.S. Pat. No. 6,398,972, Blasetti et al., issued Jun. 4, 2002; U.S. Pat. No. 6,649,072, Brandt et al., issued Nov. 18, 2003; U.S. Pat. No. 6,790,371, Dolocek, issued Sep. 14, 2004; U.S. Pat. No. 7,011,852, Sukavaneshvar et al., issued Mar. 14, 2006; U.S. Pat. No. 7,179,391, Leach et al., issued Feb. 20, 2007; U.S. Pat. No. 7,374,678, Leach et al., issued May 20, 2008; U.S. Pat. No. 7,223,346, Dorian et al., issued May 29, 2007; and U.S. Pat. No. 7,708,152, Dorian et al., issued May 4, 2010.
In addition to the GPS® Platelet Concentrate and Separation Systems, a variety of other commercially available devices may be used to isolate platelet-rich plasma, including the Magellan™ Autologous Platelet Separator System, commercially available from Medtronic, Inc. (Minneapolis, Minn., USA); SmartPReP™ commercially available from Harvest Technologies Corporation (Plymouth, Mass., USA); the AutoloGel™ Process, commercially available from Cytomedix, Inc. (Rockville, Md., USA); the GenesisCS System, commercially available from EmCyte Corporation (Fort Myers, Fla., USA); the PCCS System, commercially available from Biomet 3i, Inc. (Palm Beach Gardens, Fla., USA); and the Arthrex ACP™ Double Syringe System, commercially available from Arthrex, Inc. (Naples, Fla., USA).
Referring again to
A liquid containing white blood cells may be prepared by admixing cells with a suitable liquid, as shown in step 125, using methods known in the art. For example, white blood cells may be isolated from whole blood by lysing red blood cells or by centrifugation of whole blood utilizing a density gradient where the white blood cells sediment to the bottom of a centrifuge tube. An example of density centrifugation includes the Ficoll-Paque™ Plus (GE Healthcare Bio-Sciences, Piscataway, N.J., USA). In some cases, a density gradient may be used to further separate mononuclear and polymorphonuclear cells. White blood cells may also be prepared from whole blood using filtration; an example includes the Acelere™ MNC Harvest System (Pall Life Sciences, Ann Arbor, Mich., USA). White blood cells can also be obtained from bone marrow. The white blood cells may be then suspended in a suitable medium, such as plasma, so as to maintain their viability.
Other methods may be used to create platelet-rich plasma or other liquid containing white blood cells. For example, whole blood can be centrifuged without using a buoy system, whole blood may be centrifuged in multiple stages, continuous-flow centrifugation can be used, and filtration can also be used. In addition, a blood component including platelet-rich plasma can be produced by separating plasma from red blood cells using a slow speed centrifugation step to prevent pelleting of the platelets. In other embodiments, the buffy coat fraction formed from centrifuged blood can be separated from remaining plasma and re-suspended to form platelet-rich plasma.
Obtaining a Cytokine Cell Suspension from Adipose Tissue
In embodiments comprising the use of adipose tissue, the adipose tissue may be used directly in contacting the solid extraction material, as exemplified in step 140 of
For example, adipose tissue can be collected by suction-assisted tumescent liposuction inside a specialized collection container attached to suction hoses and to a liposuction cannula. The collection container can have a gauze-type grid filter that allows the tumescent fluid to pass through and retains the solid adipose tissue. After collecting the adipose tissue, the collection container is removed from the suction device and reattached to a centrifugation device. The filter unit may further contain a filter having approximately a 100 micrometer pore size. Once the collection container containing the adipose tissue is attached to the centrifugation device, the tissue is sonicated. After sonication, the entire apparatus is inserted into a centrifuge bucket and centrifuged at, for example, 300×g for 5 minutes. After centrifugation, the collection container together with the filter unit is detached and can be discarded. The pellet containing the stromal cells can then be re-suspended in biocompatible solutions, such as plasma, plasma concentrate and platelet-rich plasma.
Various methods and devices for isolating and/or fractionating adipose tissue and adipocytes include those as described by U.S. Pat. No. 7,374,678, Leach, issued May 20, 2008; U.S. Pat. No. 7,179,391 to Leach et al., issued Feb. 20, 2007; U.S. Pat. No. 7,992,725, Leach et al., issued Aug. 9, 2011; U.S. Pat. No. 7,806,276, Leach et al., issued Oct. 5, 2010; and U.S. Pat. No. 8,048,297, Leach et al., issued Nov. 1, 2011. A device, such as the GPS™ Platelet Concentrate System, commercially available from Biomet Biologics, LLC (Warsaw, Ind., USA), may be used to isolate adipocytes.
Obtaining a Liquid Containing White Blood Cells from Bone Marrow
In embodiments comprising the use of bone marrow, the marrow may be used directly in contacting the solid extraction material, as exemplified in step 140 of
An exemplary process for isolating and creating a bone marrow concentrate (cBMA) is diagrammed in
Once a selected volume of the BMA is obtained in step 605, it may be separated and concentrated using a gravimetric separator. Separators among those useful herein are operable to separate a multi-component fluid that generally includes various components or constituents of varying densities that are commingled or mixed together, including those described above for separation of fractions from blood and adipose tissue. The separator may include a buoy that is of a selected density relative to BMA. Such separators include those described above for use in concentrating and isolating fractions from blood and adipose tissue, including those described in U.S. Pat. No. 7,374,678, Leach, issued May 20, 2008; U.S. Pat. No. 7,179,391 to Leach et al., issued Feb. 20, 2007; U.S. Pat. No. 7,992,725, Leach et al., issued Aug. 9, 2011; U.S. Pat. No. 7,806,276, Leach et al., issued Oct. 5, 2010; and U.S. Pat. No. 8,048,297, Leach et al., issued Nov. 1, 2011. A device, such as the GPS™ Platelet Concentrate System, commercially available from Biomet Biologics, LLC (Warsaw, Ind., USA), may be used to isolate adipocytes. Separators and methods that may be used to fractionate BMA at steps 610 and 615 are also described, for example, in U.S. Application Publication No. 2006/0278588, Woodell-May, published Dec. 14, 2006. The BMA may be positioned in a separator according to various embodiments in step 610. Once the BMA is positioned in the separator, a selected fraction of the BMA may be separated from the BMA in step 615.
Once the BMA is placed in the separator, separator is spun in a centrifuge in a range between about 1,000 and about 8,000 RPM. This produces a force between about 65 and about 4500 times greater than the force of normal gravity, as generally calculated in the art, on the separator and the BMA. At this force, the more dense material in a BMA sample is forced toward the bottom end of the tube. The separator can thus be used to remove nucleated cells from the bone marrow sample. In various embodiments, concentrated BMA has a concentration of nucleated cells that is at least 2, at least 3, at least 4, or at least 5 times the concentration of nucleated cells in BMA.
Obtaining a Cytokine Cell Suspension from Blood Clots
In other embodiments comprising the use of blood, a liquid comprising cytokine-producing cells may be trapped in a blood clot. Cell releasate can be generated from the blood clot by either compression (“squeezing”), clot disruption, or centrifugation. The blood clot can be made with or without anticoagulant and with or without exogenous thrombin by combining blood or a blood fraction with a clotting agent. Suitable clotting agents include thrombin (e.g., bovine, recombinant human, pooled human, or autologous), autologous clotting protein, and polyethylene glycol. Calcium may be in the form of a calcium salt, such as calcium chloride.
In some embodiments, the clotting agent comprises a clotting protein. A suitable clotting fraction can be obtained by a process of: loading whole blood or plasma with a calcium solution (e.g., calcium chloride in ethanol) into a blood isolation device; optionally heating the whole blood or plasma for at least about 20 minutes, at a temperature of at least about 20° C.; and isolating the clotting fraction. The isolating may be performed by centrifuging the heated whole blood or plasma. A suitable isolation device is commercially available as the Clotalyst™ Autologous Thrombin Collection System (hereinafter “Clotalyst System”), sold by Biomet Biologics LLC, Warsaw, Ind., USA.
An exemplary procedure for producing a clotting agent using a device 400 of
The contents of the blood component separation device 400 are mixed by repeatedly inverting the device 400, e.g. about twelve times, so as to contact the blood with the glass beads. After mixing, the device is incubated The incubation process can be at a temperature and for a duration that will permit the contents of the device 400 to be heated at about 25° C. for about 15 minutes. Upon completion of the incubation period, a clotted mass of red blood cells, blood plasma, and glass beads forms at a second end 406 of the main chamber 405. After incubation is complete, the device 400 is shaken enough to dislodge and break-up any gel that may be present.
Obtaining a Cytokine Suspension Using Non-Centrifugal Methods
As noted above, the liquid containing white blood cells can be obtained by non-centrifugal means, such as by culturing. As referred to herein, a “non-centrifugal method” comprises a process for obtaining tissue fractions comprising cytokine-producing cells from tissue without use of a centrifuge. In some embodiments, methods are “non-gravimetric,” wherein, based on physical, chemical or physicochemical properties of the cells other than density, wherein the concentration of white blood cells in the fraction are higher than the concentration of white blood cells in the tissue. Such non-gravimetric methods are, in particular, distinguished from methods wherein a white blood cell fraction is created by centrifugation of whole blood or other tissue. In some embodiments, the non-centrifugal method comprises a process solely based on such properties of white blood cells other than density. Non-centrifugal methods include filtration, antibody binding, and electrophoretic methods.
For example, as discussed above, white blood cells may be prepared from whole blood, bone marrow aspirate or other tissue, using filtration. White blood cells and other cytokine-producing cells obtained from blood, bone marrow, adipose tissue or other sources may also be cultured, using methods among those known in the art. The cells may be then suspended in a suitable medium, such as plasma, so as to maintain their viability and facilitate mixing or other contact with a solid extraction material. A liquid containing the cells may also be produced by compression or disruption of blood clots, as described above.
Contacting a Cytokine Cell Suspension with an Extraction Material and Isolating a Protein Solution
In further reference to the exemplified process of
The solid extraction material can include various materials that provide a particular surface area to contact the cells. The solid extraction material may be a continuous material or may be discontinuous and comprise a plurality of separate particles. For example, the solid extraction material may be in the form of a plurality of beads, fibers, powder, a porous material, or a surface of a container comprising the liquid containing the cells. The solid extraction material may comprise geometric forms having various cross-sectional shapes, such as spherical, oval, or polygonal, among others. The solid extraction material can also comprise a continuous porous network, similar to a sponge, or can include a plurality of individual porous particles. The solid extraction material may also provide a larger surface area by being porous in comparison to a non-porous material.
In some embodiments, the solid extraction material includes particles having a large aspect ratio, for example, where the particles are needle-like in shape. The solid extraction material may also be formed as long fibers and may be or take a form similar to glass wool.
In some cases, the solid extraction material can comprise the internal walls of a container holding the cytokine cell suspension. For example, the solid extraction material may comprise the lumen of a syringe that contains the cytokine cell suspension. Other containers include tubes, such as centrifuge tubes, or a blood fractionation device or concentrator assembly as described elsewhere herein.
Where the solid extraction material is a continuous material, such as a porous sponge-like material, the solid extraction material can be used in an amount sufficient to absorb or adsorb or include substantially the entire liquid volume of white blood cells within the pores or interstices of the solid extraction material. Where the solid extraction material is a discontinuous material, such as a plurality of particles, the solid extraction material can be combined with the liquid containing the cells to form a slurry-like composition. The slurry can vary in consistency from paste-like, having a high-solids fraction, to a readily flowable slurry having a low-solids fraction.
The solid extraction material can provide a large surface area with which to contact the cells. However, in some cases, the solid extraction material can be further treated to increase its surface area, for example, by physically or chemically etching or eroding the surface of the solid extraction material. With respect to chemical etching, a corrosive agent can be used to modify the surface of the solid extraction material depending on the nature of the material. The modified surface may be produced by employing an alkali or an acid, for example chromosulphonic acid, in particular about 20% to about 80% in strength, preferably about 50% chromosulphonic acid. The solid extraction material can be incubated with the corrosive agent for about 5 min to about 30 min in order to chemically etch the surface and increase the surface area. The solid extraction material can then be washed to remove the corrosive agent. For example, the solid extraction material can include the internal walls of a container for holding the cytokine cell suspension where the internal walls are etched to subsequently increase the surface area in contact with the liquid.
Various polymers, metals, ceramics, and glasses can be used as the solid extraction material. In some embodiments, the solid extraction material comprises a hygroscopic material. Examples of suitable solid extraction material materials include glasses, minerals, polymers, metals, and polysaccharides. Minerals include corundum and quartz. Polymers include polystyrene, polyethylene, polyvinyl chloride, polypropylene, and polyacrylamide. Metals include titanium. Polysaccharides include dextran and agarose. A preferred solid extraction material comprises, or consists essentially of, polyacrylamide, as further described below.
The solid extraction material may comprise, for example, continuous solid extraction material of glass or a plurality of glass particles, glass wool, a continuous solid extraction material of metal such as titanium, a plurality of metal beads, metal powder, and combinations thereof. A continuous solid extraction material of metal can include a block or other three-dimensional shape formed of porous metal or metal alloys with an open cell structure. The solid extraction material may include various beads or particles of various sizes including substantially spherical beads. Beads include polystyrene beads, polyacrylamide beads, glass beads, metal (e.g., titanium) beads, or any other appropriate beads. Beads may be any size appropriate for the container and the amount of cytokine cell suspension being used. In some instances, bead sizes can range from about 0.001 millimeters to about 3 millimeters in diameter. Where the bead size is sufficiently small, the beads can appear more like a powder.
Polyacrylamide beads used as the solid extraction material can be formed by polymerizing acrylamide monomer using controlled and standardized protocols as known in the art to produce relatively uniform beads formed of polyacrylamide gel. In general, polyacrylamide is formed by polymerizing acrylamide with a suitable bifunctional crosslinking agent, most commonly N,N′-methylenebisacrylamide (bisacrylamide). Gel polymerization is usually initiated with ammonium persulfate and the reaction rate is accelerated by the addition of a catalyst, such as N,N,N′,N′-tetramethylethylenediamine (TEMED). In various embodiments, polyacrylamide beads comprise 0.5 micromole of carboxyl groups per milliliter of beads, imparting a slight anionic character (negative charge). The beads are also typically resistant to changes in pH, and are stable in many aqueous and organic solutions. By adjusting the total acrylamide concentration, the polyacrylamide gel can be formed in a wide range of pore sizes. Moreover, the polyacrylamide beads can be formed in many sizes and can have relatively uniform size distributions. Bead size may range from several micrometers in diameter to several millimeters in diameter. For example, various types of Bio-Gel™ P polyacrylamide gel beads (Bio-Rad Laboratories, Hercules, Calif., USA) have particle sizes ranging from less than about 45 μm up to about 180 μm. Polyacrylamide beads are also available from SNF Floerger (Riceboro, Ga., USA), Pierce Biotechnology, Inc. (Rockford, Ill., USA), and Polymers, Inc. (Fayetteville, Ark., USA).
Once polymerized, polyacrylamide beads can be dried and stored in a powder-like form. The dry beads are insoluble in water but can swell considerably upon being rehydrated. Rehydration returns the polyacrylamide beads to a gel consistency that can be from about two to about three times the dry state size. Thus, dry polyacrylamide beads (i.e., desiccating polyacrylamide beads) may be used to absorb a portion of a liquid volume, including solutes smaller than the bead pore size, and can serve to concentrate IL-1ra and other proteins produced by the white blood cells. For example, combining dry polyacrylamide beads with the blood and/or platelet-rich plasma activates production of IL-1ra by the white blood cells and also reduces the total liquid volume as the dry beads rehydrate and swell.
Without limiting the scope, mechanism or function of the present technology, it has been discovered that surface contact with the solid extraction material can activate the cells and the solid extraction material can, in some cases, assist in the separation and concentration of the resulting Protein Solution rich in cytokines, including IL-1ra. For example, in the case of a porous solid extraction material, a portion of the liquid comprising the cells can enter the pores and remain therein. Cells in the liquid may contact this additional surface area. In some embodiments, the pores are too small for the cells to enter, but a portion of the liquid can enter the pores. Liquid can be removed from the solid extraction material and pores by centrifuging, for example.
The solid extraction material is preferably sterilized, using techniques among known in the art, in order to prevent contamination of the cytokine cell suspension. For example, heat and pressure sterilization methods, such as autoclaving, may be used depending on the particular composition of the solid extraction material. Alternative methods, such as chemical sterilization or irradiation, can be used where the solid extraction material may be adversely affected by the autoclaving process.
In some embodiments, the cytokine cell suspension is incubated with solid extraction material for a time effective to remove a portion of the liquid. The incubation may be carried out over a period from about 30 seconds to about 72 hours and may be carried out at a temperature from about 20° C. to about 41° C. For example, the incubation may be 24 hours or less, 10 hours or less, 5 hours or less, 2 hours or less, 1 hour or less, 30 minutes or less, 15 minutes or less 10 minutes or less, 5 minutes or less, 4 minutes or less, 3, minutes or less, or 2 minutes or less. Incubation may be at least about 15 seconds, at least about 30 seconds, at least about 1 minutes, at least about 90 seconds, at least about 2 minutes, at least about 10 minutes, or at least about 30 minutes. In some embodiments, incubations from about 1 minute to about 3 minutes. In some embodiments, the incubation is conducted at about 37° C. In some embodiments the liquid is not incubated, but is contacted with the solid extraction material for only so long as necessary to perform subsequent processing. The contacting may occur at ambient conditions, e.g., at a temperature of about 20-25° C.
In some embodiments, the cytokine cell suspension and the solid extraction material are agitated to more thoroughly mix these components during contact. The agitation may be accomplished by inverting, shaking, rocking, stirring, or vortexing the liquid and solid extraction material. Agitation may increase contact of the cells within the liquid with the solid extraction material. Agitation may be performed once, repeated multiple times, repeated periodically, or may be continuous. The liquid comprising the cells and the solid extraction material may also be agitated while the liquid is stimulated with the electromagnetic field. Additional aspects and features relating to producing protein-rich solutions using polyacrylamide beads and other solid extraction materials are described in: U.S. Patent Application Publication No. 2009/0220482, Higgins et al., published Sep. 3, 2009; U.S. Patent Application Publication No. 2010/0055087, Higgins et al., published Mar. 4, 2010; U.S. Patent Application Publication 2011/0052561, Hoeppner, published Mar. 3, 2011; International Application Publication 2012/030593, Higgins et al., published Mar. 8, 2012; and U.S. Patent Application Publication 2012/0172836, Higgins et al., published Jul. 5, 2012. Compositions and methods useful in aspects of the present technology are also described in the following applications filed concurrently with this disclosure: U.S. patent application Ser. No. 13/841,083, Landrigan, et al., Treatment of Inflammatory Respiratory Disease Using Protein Solutions; U.S. patent application Ser. No. 13/837,005, Woodell-May et al., Methods and Acellular Compositions for Treating Inflammatory Disorders; U.S. patent application Ser. No. 13/837,480, O' Shaughnessey, et al., Treatment of Pain Using Protein Solutions; U.S. patent application Ser. No. 13/839,280, Leach et al., Methods for Making Cytokine Compositions from Tissue Using Non-Centrifugal Methods; U.S. patent application Ser. No. 13/840,129, Matusuka, et al., Treatment of Collagen Defects Using Protein Solutions; and U.S. patent application Ser. No. 13/841,103, Landrigan, et al., Treatment of Peripheral Vascular Disease Using Protein Solutions, all of which are incorporated by reference herein.
Contacting of the liquid containing white blood cells with the solid extraction material may be performed using a suitable container or other apparatus to affect the contact. Contacting may be performed in a continuous process wherein a flow of the liquid is passed over or through the solid extraction material, or the liquid and solid extraction material may be contained in a vessel. As discussed above, the vessel may comprise the solid extraction material, or may merely serve as a container holding the beads or other forms of the material. Containers useful in the present technology include those known in the art, such as the Plasmax™ Plus Plasma Concentrator, commercially available from Biomet Biologics, LLC (Warsaw, Ind., USA) and may include those devices and methods of use as described in U.S. Pat. No. 7,553,413, Dorian et al., issued Jun. 30, 2009; and U.S. Pat. No. 7,694,828, Swift et al., issued Apr. 13, 2010.
Such a device is shown in
During use, a fluid 355 containing white blood cells and, optionally, platelets is injected to the upper chamber 305 via the inlet port 330 and mixed with the polyacrylamide beads 350. The fluid 355 and polyacrylamide beads 350 may be mixed by rotating the agitator stem 320 and the gel bead agitator 325, to help mix the fluid 355 and beads 350. The mixed fluid 355 and polyacrylamide beads 350 are then incubated for the desired time at the desired temperature. The device 300 is then centrifuged so that liquid passes to the lower chamber 310 while the polyacrylamide beads 350 are retained by a filter 345, thereby separating the polyacrylamide beads 350 from the resulting solution 360 of IL-1ra and other proteins that collects in the lower chamber 310. The solution 360 may be removed from the device via outlet port 335.
In some embodiments, a Protein Solution can be made in a process wherein a liquid containing white blood cells is isolated from a tissue and then contacted with a solid extraction material in a continuous process. Referring again to
The S/C device comprises a separation region, a first concentration region, a second concentration region, a buoy system, an inlet port, a check valve, a first withdrawal port and a second withdrawal port.
A method for obtaining a Protein Solution comprises spinning the S/C device 500 by centrifugation. Centrifugal forces allow the buoy system 515 to move through the whole blood, resulting in a fraction of the whole blood to be located in the buoy separation region 535. For example, this fraction may comprise platelet-rich plasma. With a use of a withdrawal syringe, the selected fraction can be removed from the collection volume 535 through the third buoy member 530 that defines a removal passage 540 that is connected with collection passages 545. A connection elbow 550 can interconnect with the removal passage 540 to allow a vacuum to be formed through the connection elbow 550, the collection passage 540, and the buoy collection passages 545. A collection tube 555 can interconnect the connection elbow 550 with a withdrawal elbow 560 that extends from a wall 565 that can be a bottom wall of concentration region 570. A second withdrawal tube 575 can be first connected with a check valve assembly 580 and a first withdrawal port 585. The first withdrawal port 585 can be connected with the withdrawal syringe with a Luer lock type connection or other appropriate connection.
The check valve assembly 580 ensures the fraction being removed flows in one direction and prevents the fraction being removed from reentering the second withdrawal tube 575. Furthermore, when material is pushed back into the check valve assembly 580 from the first withdrawal port 585, such that material will enter the concentration region 570, a disc within the check valve assembly 580 can flex down towards the second withdrawal tube 575 and close an opening and thereby open a second opening within the check valve assembly 580. The second opening allows the fraction to be pushed into the concentration region 570.
Therefore, the blood fraction is then re-injected through the first withdrawal port 285, through the check valve assembly 580, and into an upper volume 588 of the concentration region 570. Polyacrylamide beads 590 are added to the blood fraction in the upper volume 588 and the blood fraction and the polyacrylamide beads 590 can be mixed by shaking. Optionally, the blood fraction and the beads 590 can be incubated for a selected period of time before proceeding with the method.
The method comprises a second step of spinning by centrifugation. During the second centrifugation, the anti-inflammatory cytokine composition is separated from the beads 590 by being forced through a filter 592 and into a lower concentration region 595 of the concentration region 570. The Protein Solution can be withdrawn through a third withdrawal tube 596 and out a second withdrawal port 598 by use of a second withdrawal syringe. Again, the syringe can be connected to the second withdrawal port by a Luer® lock type connection.
Referring again to
Optional Electromagnetic Stimulation
The cytokine cell suspension can be stimulated with an electromagnetic field, before or during the contacting of the liquid with a solid extraction material. Thus, in some embodiments, stimulation of the liquid comprising the cells can be performed prior to contacting the liquid and the solid extraction material. However, it is preferred that at least a portion of the contacting step and at least a portion of the stimulating step overlap in time such that the liquid comprising the cells is concurrently in contact with the solid extraction material and stimulated with the electromagnetic field.
Stimulating the cytokine cell suspension with an electromagnetic field may involve various forms of electromagnetic stimulation, such as a pulsed electromagnetic field or a capacitively coupled electromagnetic field. In some embodiments, the liquid is stimulated using a power source coupled to a stimulation coil. The current passing through the coil produces a pulsing magnetic field which induces in the liquid a pulsing electric field. The coil may partially surround the liquid as it is held within a container, such as a tube or syringe. The coil may be integrated into to the container holding the cytokine cell suspension or may be removable. For example, a plastic tube can be formed with an integrated coil or the coil can be temporarily coupled to the container or placed within the container; for example, the tube can be configured so that the coil can be snapped onto the container. The power source can be coupled to the coil as needed to perform the stimulating step.
Stimulation of the liquid with an electromagnetic field may also include placing at least two electrodes across the liquid. Electrical energy may then be applied to the electrodes so as to capacitively couple the electrodes and generate the electromagnetic field there between. The electromagnetic field is therefore able to pass through the liquid so as to increase the rate and/or amount of cytokine production. In other embodiments, electrodes can be used to produce a direct current or one or more coils can be used to produce a pulsed electromagnetic field.
The strength of the electromagnetic field during stimulation can be at least about 0.5 microvolts per centimeter, whether produced by direct current, capacitively coupled current, or pulsed electromagnetic field. In the case of a direct current electrode, the amplitude of the current can be from about 1 to about 200 microamperes, and in some embodiments, the amplitude may be from about 20 to about 100 microamperes. In still further embodiments, the current may be about 20, about 60, or about 100 microamperes. It should be understood, however, that the amplitude of the current may be of other suitable magnitudes.
The electromagnetic field applied during the stimulating step may be constant or vary over time. For example, a sinusoidal time varying electromagnetic field can be applied using the electrodes placed across the liquid. Such a sinusoidal time varying electromagnetic field can have a peak voltage across the electrodes from about 1 volt to about 10 volts, and in some embodiments, the peak voltage can be about 5 volts. The corresponding electric field produced can have an amplitude of from about 0.1 millivolt per centimeter (mV/cm) to about 100 mV/cm, and in some embodiments can be about 20 mV/cm. The sinusoidal time varying electric field may have a frequency of from about 1,000 Hz to about 200,000 Hz, and in some embodiments the frequency may be about 60,000 Hz.
The electromagnetic field applied to the liquid may also be a pulsed electromagnetic field. The pulsed electromagnetic field can be induced using an external coil and a pulse generator. In this regard, a pulsed electromagnetic field may have a pulse duration of from about 10 microseconds per pulse to about 2000 microseconds per pulse. The pulse duration in one embodiment can be about 225 microseconds. The pulses may include electromagnetic bursts, in which a burst can comprise from 1 pulse to about 200 pulses. Alternatively, the electromagnetic field may have bursts that comprise from about 10 pulses to about 30 pulses. In this regard, in one embodiment each burst may comprise about 20 pulses.
The frequency at which bursts in the pulsed electromagnetic are applied may vary. In this regard, bursts can be repeated at a frequency of from about 1 Hz to about 100 Hz in some embodiments, and can be repeated at a frequency of about 10 Hz to about 20 Hz in other embodiments. Furthermore, bursts can repeat at a frequency of about 1.5 Hz, about 15 Hz or about 76 Hz. A burst can have a duration from about 10 microseconds up to about 40,000 microseconds. In this regard, a burst can have a duration of about 4.5 milliseconds.
Suitable devices for generating a capacitively coupled electromagnetic field include SpinalPak® spinal stimulator (EBI, L.P., Parsippany, N.J.) or a DC stimulation device such as an SpF® XL IIb spinal fusion stimulator (EBI, L.P., Parsippany, N.J.). Pulsed electromagnetic fields can be produced using various known methods and apparatuses, such as using a single coil or a pair of Helmholtz coils. For example, a suitable apparatus includes the EBI Bone Healing System® Model 2001 (EBI, L.P., Parsippany, N.J.) and the BTBS stimulation coil. With respect to direct current, an electric field may be generated using any known device for generating a direct current electric field, such as for example, the Osteogen™ implantable bone growth stimulator (EBI, L.P., Parsippany, N.J.). Other suitable devices for generating electromagnetic fields may be used.
Electromagnetic stimulation of the cytokine cell suspension can be continued and/or repeated as desired with respect to contacting the liquid and the solid extraction material. It should be understood, however, that the step of stimulating the liquid with an electromagnetic field includes fields other than, or in addition to, electric or electromagnetic fields associated with ambient conditions (such the electromagnetic fields generated by casual exposure to radios, telephones, desktop computers or similar devices).
In some embodiments, both the contacting and stimulating steps as shown in
Other Methods for Forming Protein Solutions
The present technology provides other methods for forming components of Protein Solutions, such as the admixture of proteins and other components and the isolation and concentration of proteins and components without using solid extraction materials. For example, Protein Solutions of the present technology can be made by mixing of proteins made by such methods with components or solutions made by tissue isolation from allogeneic sources and processing with solid extraction materials, as described above.
For example, various methods provide acellular or substantially acellular Protein Solutions, comprising one or more proteins as described above. Without limiting the scope, mechanism or function of the present technology, such acellular anti-inflammatory cytokine compositions may offer advantages in certain applications, insofar as they may not create an immunogenic response in subjects to whom they are administered.
In particular, by way of example, a Protein Solution may comprise interleukin-1 receptor antagonist (IL-1ra) that is synthetic or recombinant, or isolated from autologous, allogeneic or xenogeneic blood or other biologic sources, aside from the methods described above. For example, Kineret™ (anakinra) is a recombinant, non-glycosylated form of IL-1ra, sold by Amgen Manufacturing, Ltd. (Thousand Oaks, Calif.). Various recombinant interleukin-1 inhibitors and methods of treatment are described in U.S. Pat. No. 6,599,873, Sommer et al., issued Jul. 29, 2003; U.S. Pat. No. 5,075,222, Hannum et al., issued Dec. 24, 1991; and U.S. Application Publication No. 2005/0197293, Mellis et al., published Sep. 8, 2005. In addition, methods for producing IL-1ra from body fluids, including the use of autologous fluids, are described in U.S. Pat. No. 6,623,472, Reinecke et al., issued Sep. 23, 2003; U.S. Pat. No. 6,713,246, Reinecke et al., issued Mar. 30, 2004; and U.S. Pat. No. 6,759,188, Reinecke et al., issued Jul. 6, 2004. When an allogeneic anti-inflammatory cytokine composition is to be generated, multiple sources of IL-1ra from multiple subjects may be pooled together.
More generally, methods for making acellular Protein Solutions can comprise culturing cells in a cell culture that either naturally produce anti-inflammatory cytokines, such as IL-1ra, or cells that are engineered to produce such cytokines. Non-limiting examples of cells that naturally produce anti-inflammatory cytokines include adipose tissue cells, adipocytes, adipose-derived stem cells, stromal cells, bone marrow cells, mesenchymal stem cells, and blood cells.
In various embodiments, cell lines can be engineered to overproduce an anti-inflammatory cytokine. Non-limiting examples of anti-inflammatory cytokines include VEGF, TNF-α, IL-1ra, sTNF-RI, sTNF-RII, PGDF-AB, PDGF-BB, IGF-I, EGF, TGF-β1, sIL-1RII, and HGF. Stable eukaryotic cell lines can be generated that overexpress an anti-inflammatory cytokine by transfecting eukaryotic cells, such as mammalian cells, with recombinant DNA comprising a gene encoding an anti-inflammatory cytokine and a selectable marker. Alternatively, prokaryotes and yeast can be engineered to overexpress an anti-inflammatory cytokine by transformation with recombinant DNA comprising a gene encoding an anti-inflammatory cytokine and a selectable marker. Transformations and transfections can be performed with recombinant DNA molecules comprising a DNA sequencing encoding an anti-inflammatory cytokine, such as IL-1ra, and a selectable marker. Eukaryotic and prokaryotic cells can be engineered to overexpress the anti-inflammatory cytokine constitutively or by induction. Methods for expressing anti-inflammatory cytokines, such as IL-1ra, sTNF-RI, and sTNF-RII, and sIL1-RII in eukaryotic and prokaryotic cells are described in U.S. Pat. No. 6,337,072, Ford et al., issued Jan. 8, 2002; and U.S. Application Publication No. 2001/0053764, Sims et al., published Dec. 20, 2001.
When a IL-1ra gene is transcribed in humans, the mRNA can be spliced into four variants, resulting in four isoforms of translated IL-1ra. SEQ ID NOs: 1, 3, 5, and 7 are the cDNAs for IL-1ra isoforms 1-4 respectively, and SEQ ID NOs: 2, 4, 6, and 8 are the amino acid sequences of IL-1ra isoforms 1-4 respectively. Collectively, the IL-1ra isoforms are referred to as “IL-1ra.” SEQ ID NO: 9 is the cDNA sequence for sTNF-RI and SEQ ID NO:10 is the amino acid sequence for sTNF-RI. SEQ ID NO:11 is the cDNA sequence for sTNF-RII and SEQ ID NO:12 is the amino acid sequence for sTNF-RII. SEQ ID NO:13 is the cDNA sequence for sIL-1RI and SEQ ID NO:14 is the amino acid sequence for sIL-1RI. SEQ ID NOs 15 and 17 are the cDNAs for sIL-1RIIv1 and sIL-1RIIv3 respectively, and SEQ ID NOs:16 and 18 are the amino acid sequences for sIL-1RIIv1 and sIL-1RIIv3 respectively. The cDNA sequence for IL-1RIIv2 is a non-coding sequence; therefore, it is not included.
To express either IL-1ra, sTNF-RI, or sTNF-RII (generically referred to as a “protein of interest”) in a prokaryotic culture, for example in a particular bacteria, a cDNA sequence (SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, or 17) is cloned into an expression vector suitable for the bacteria. The expression vector should comprise a strong promoter, and a selectable marker, such as antibiotic resistance. Non-limiting examples of antibiotics capable of killing bacteria cells include ampicillin, tetracycline, kanamycin, and chloramphenicol. The expression vector should further comprise elements that result in constitutive or inducible expression of the protein of interest. Optionally, a DNA sequence corresponding to a tag functionally coupled to the protein of interest that allows for identification and purification of the protein can be present in the vector adjacent to the gene for the protein of interest. For example, an N or C-terminal His tag can be used to detect proteins with anti-His antibodies, and they allow for purification on nickel columns. When the expression vector comprising a gene expressing a protein of interest is prepared, a bacteria cell, for example E. coli, can be transformed with the expression vector. The selectable marker ensures that only cells transformed with the vector will survive in LB broth supplemented with an antibiotic corresponding to the selectable marker. The bacteria can then be grown in LB broth supplemented with the antibiotic for expression and purification. Expression vectors, methods for cloning a protein of interest into an expression vector, methods for transforming prokaryotic cells, methods for expressing protein from transformed prokaryotic cells, and protein purification methods are commonly known by those with ordinary skill in the art.
To express a protein of interest in a eukaryotic culture, for example in mammalian cells, a cDNA sequence (SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, or 17) is cloned into an expression vector suitable for a particular mammalian cell. The expression vector should comprise a strong promoter, and a selectable marker, such as antibiotic resistance. Non-limiting examples of antibiotics capable of killing mammalian cells include geneticin and gentamicin. The expression vector should further comprise elements that result in constitutive or inducible expression of the protein of interest. Optionally, a DNA sequence corresponding to a tag functionally coupled to the protein of interest that allows for identification and purification of the protein can be present in the vector adjacent to the gene for the protein of interest. When the expression vector comprising a gene expressing a protein of interest is prepared, a mammalian cell, such as a human cell, can be transfected with the expression vector. Transfected cells can be grown in a cell culture medium supplemented with an antibiotic corresponding to the selectable marker. The presence of the antibiotic allows for the isolation of stable cell lines. Stable cell lines can then be grown in cell culture medium supplemented with antibiotic for expression and purification. Expression vectors, methods for cloning a protein of interest into an expression vector, methods for transfecting eukaryotic cells and developing stable cell lines, methods for expressing protein from transfected eukaryotic cells, and protein purification methods are commonly known by those with ordinary skill in the art.
Alternatively, eukaryotic cells that have not been genetically altered by DNA transfection can be cultured. The eukaryotic cells can be primary cultures, i.e. cells grown directly from a eukaryotic donor, such as a human, or the eukaryotic cells can be established cell lines. Many established cell lines are available commercially from American Type Culture Collection, Inc. (Manassas, Va., USA). The cells can be grown with or an exogenous signal, such as a recombinant protein. Eukaryotic cells are often cultured in culture flasks with cell culture medium. The cell culture medium can be recovered from the flasks, and centrifuged to remove any non-adherent cells.
A cell culture can be a monolayer culture, a non-adherent culture, or a bioreactor. A monolayer culture comprises anchorage-dependent cells that are cultured on a suitable substrate that allows cell adhesion and spreading, such as cell culture flasks and cell culture dishes. A non-adherent culture comprises cells that are maintained in a suspension. Suitable cells are either not anchorage-dependent, or they are anchorage-dependent cells that have been adapted for culture in a suspension. Many cell lines, for example many insect cells, can be grown in either a monolayer or a suspension. A bioreactor is a device that can support a biologically active environment in which chemical processes are carried out and/or biochemically active substances are derived. Bioreactors can include suspended or immobilized cells. Monolayer cultures, non-adherent cultures, and bioreactors can be maintained by methods commonly used in the art.
In some embodiments, the cell culture is subjected to an electromagnetic field, so as to stimulate the production of one or more proteins. Stimulating the culture with an electromagnetic field may involve various forms of electromagnetic stimulation, such as a pulsed electromagnetic field or a capacitively coupled electromagnetic field. Methods and conditions for stimulation include those discussed above.
Cell cultures can either release anti-inflammatory cytokines into culture medium naturally, or the cultures can be induced to release the anti-inflammatory cytokines into the culture medium. The culture medium can be isolated by aspiration, centrifugation or filtration for use in forming the acellular anti-inflammatory cytokine composition.
In some embodiments, an anti-inflammatory cytokine is isolated from urine, for use in producing a Protein Solution of the present technology. Proteins can be isolated from urine by methods among those known in the art. One such method is employed in the ProteoSpin™ Urine Protein Concentration Maxi Kit sold by Norgen Biotek Corp. (Thorold, Ontario, Canada). This kit utilizes an ion exchange resin integrated into a spin column. Briefly, a urine sample is obtained and its pH adjusted to 3.5. The urine is then transferred to a spin column containing the ion exchange resin, which is placed in a collection tube. The column is then centrifuged, wherein the proteins attach to the resin, and the remaining fluids and salts flow into the collection tube and are discarded. The proteins are then washed by applying supplied column activation and wash buffer followed by centrifugation. The flow through is discarded and the wash procedure is repeated. An elution buffer (10 mM sodium phosphate, pH 12.5) is added to the column and neutralizer is added to an elution tube. The spin column containing the elution buffer is placed in the elution tube and centrifuged, whereby the proteins are eluted and captured in the elution tube containing neutralizer.
The present technology also provides compositions comprising a Protein Solution and a second component comprising active materials, physiological carriers, and combinations thereof. In some embodiments, compositions comprise a safe and effective amount of the Protein Solution and a safe and effective amount of a second active. A “safe and effective” amount of a component is an amount that is sufficient to have the desired therapeutic effect in the human or other mammalian subject, without undue adverse side effects (such as toxicity, irritation, or allergic response), commensurate with a reasonable benefit/risk ratio when used in the manner of this technology. The specific safe and effective amount of the component will, obviously, vary with such factors as the particular condition being treated, the physical condition of the patient, the nature of concurrent therapy (if any), the specific components used, the specific route of administration and dosage form, the carrier (if any) employed, and the desired dosage regimen.
Active materials among those useful herein include biologics and pharmaceutical actives. Biologics include blood fractions, such as PRP, blood products, and concentrated bone marrow aspirate (cBMA).
Accordingly, in some embodiments, the present technology provides compositions comprising a safe and effective amount of a Protein Solution and a safe and effective amount of cBMA. cBMA can include hematopoietic, stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, white blood cells, fibroblasts, reticulocytes, adipose cells, or endothelial cells. As described above, the Protein Solution may be made using bone marrow aspirate as a cytokine containing tissue. However, a therapeutic composition may additionally comprise cBMA with Protein Solution. In one embodiment, a therapeutic composition comprises a Protein Solution and cBMA in an Protein Solution:cBMA ratio of about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9 or about 1:10. Alternatively, the Protein Solution:cBMA ratio can be about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1 or about 10:1. The cBMA and Protein Solution may also be produced simultaneously. Thus, in reference to
Pharmaceutical actives among those useful herein include herein include organic molecules, proteins, peptides, peptidomimetics, nucleic acids, nucleoproteins, antisense molecules, polysaccharides, glycoproteins, lipoproteins, carbohydrates and polysaccharides, botanical extracts, and synthetic and biologically engineered analogs thereof, living cells (other than white blood cells stromal cells) such as chondrocytes, bone marrow cells, viruses and virus particles, natural extracts, and combinations thereof. Specific non-limiting examples of bioactive materials include hormones, antibiotics and other anti-infective agents, hematopoietics, thrombopoietics, antiviral agents, antitumor agents (chemotherapeutic agents), antipyretics, analgesics, anti-inflammatory agents, antiallergy agents, vasodilators, cytokines, growth factors, gene regulators, vitamins, minerals and other nutritionals, nutraceuticals and combinations thereof. In particular, actives include bronchodilators (such as albuterol, levabuterol, irbuterol, ipatropium, salmeterol, and formoterol), glucocortico steroids (such as mometasone, fluticasone, budesonide, and beclomethosone), antibiotics, antivirals, and combinations thereof. In some embodiments, compositions may comprise growth factors in addition to those present in the Protein Solution, such Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor Beta (TGF-β), Insulin-Like Growth Factor (IGF), Fibroblast Growth Factor (FGF), Epidermal Growth Factor (EGF), Vascular Endothelial Growth Factor (VEGF), and Bone Morphogenetic Proteins (BMPs).
The compositions may comprise a carrier material, in addition to any liquid comprising the Protein Solution. It should be understood that in various embodiments of the present technology, methods of treatment employ the Protein Solution as comprised and made above, without further carrier, by direct injection or other application to the site of treatment. However, in other embodiments, an additional carrier material may be used for such reasons as for ease of administration, to facilitate administration using a particular delivery device, enhancing activity, an increasing the length of time the Protein Solution remains at the site of administration. Carriers among those useful herein include saline, hyaluronic acid, collagen, buffers (such as Hank's Buffer), cell culture media, blood products (such as PRP and platelet poor plasma), and mixtures thereof.
Protein Solutions, and compositions comprising Protein Solutions may be sterilized prior to administration, by any suitable method. For example, a Protein Solution may be sterilized by including a sterile filter to process the product made by the processes described above. In some embodiments, an antibiotic may be included in the solid extraction material during the contacting step described above, or may be added at one or more of the various steps in the methods and treatments described herein. Alternatively, or in addition, the Protein Solution may be produced asceptically.
Protein Solutions and compositions comprising Protein Solutions may also be lyophilized (freeze drying, or cryodesiccation) after production, using methods among those known in the art. Thus, as depicted in
The present technology provides compositions comprising components derived from blood or other tissue that are suitable for allogeneic administration. In particular, such compositions may comprise proteins and other components isolated from a mammalian subject, or a plurality of mammalian subjects, other than the subject to whom the composition is to be administered in a method of this technology. In some embodiments, Protein Solutions comprise components isolated from the subject to be treated and components isolated from one or more subjects other than the subject to be treated.
Methods of the present technology include those wherein a Protein Solution or components thereof are isolated from blood obtained from mammalian blood donors other than the subject to be treated, such as may be obtained from a blood bank. In some embodiments, the blood may typed according to the ABO blood typing system so as to assess compatibility with the blood of the donor. In other embodiments, the blood is not typed. The blood may be obtained from multiple donors, and mixed (“pooled”) as part of the obtaining steps discussed above.
In further reference to
In some embodiments, the composition can be processed to remove white blood cells (or other cytokine-producing cells) present in the Protein Solution composition after contacting step 140. Methods for removing white blood cells include those known in the art, including filtering, clotting, and gravimetric methods. Isolating the blood fraction comprising plasma and removing white blood cells may performed essentially simultaneously. Thus, the present technology provides methods for making a non-immunogenic anti-inflammatory cytokine composition, comprising:
In other embodiments, the Protein Solution is not freeze dried after contacting, and cells are not removed. In such embodiments, a crypreservative storage solution may be added to the composition, to provide stability for subsequent storage at reduced temperatures. Suitable storage solutions include those in the art, such as glycerol and dimethylsulfoxide (DMSO). The composition may be stored at reduced temperatures, such as from about 1° C. to about 6° C. In some embodiments, the composition is stored under liquid nitrogen, at about −80° C. Preferably, the cryopreservative storage solution is removed from the Protein Solution prior to administration to a mammalian subject. Removal of the storage solution may be performed by methods including those known in the art for processing stored blood comprising cryopreservatives. Washing may be performed using a wash solution, such as saline. In such embodiments, the blood type of the subject to be treated may be matched to the blood type of the donor from whom the cytokine cell suspension was obtained.
The present technology provides methods for the treatment of an inflammatory disorder or other disorder mediated by IL1-ra in a human or other mammalian subject, comprising administration of a Protein Solution of the present technology the subject. Methods include treating an inflammatory disorder using a Protein Solution that is made by contacting a cytokine cell suspension with a solid extraction material, wherein the liquid is whole blood, bone marrow aspirate, adipose tissue, or fractions thereof obtained from a donor that is not the subject.
Without limiting the mechanism, utility or function of the present technology, the methods and treatments of this technology mediate the effects of interleukin-1 and its role in the inflammation cascade. As generally discussed above, interleukin-1 (IL-1) includes a family of cytokines that can stimulate lymphocytes, neutrophils, and macrophages, activate phagocytes, increase airway fibrosis, promote lymphocyte nodules in the airways, increase production of both MMP-9 and MMP-12, and are involved in many chronic inflammatory conditions. IL-1 can be generated by macrophages, monocytes, and dendritic cells, and can be part of the inflammatory response against infection. See, Lappalainen et al., “Interleukin-1β Causes Pulmonary Inflammation, Emphysema, and Airway Remodeling in the Adult Murine Lung” American Journal of Respiratory Cell and Molecular Biology, vol. 32, no. 4, pages 311-318 (April 2005).
The mode of action of IL-1 can be mediated by IL-1ra. IL-1ra binds to the same receptor on the cell surface as IL-1, and thus prevents IL-1 from sending a signal to that cell. IL-1ra is secreted from white blood cells, including monocytes, macrophages, neutrophils, polymorphonuclear cells (PMNs), and other cells, and can modulate a variety of IL-1 related immune and inflammatory responses, as described by Arend W P, Malyak M, Guthridge C J, Gabay C (1998) “Interleukin-1 receptor antagonist: role in biology” Annu. Rev. Immunol. 16: 27-55. Production of IL-1ra is stimulated by several substances including adherent immunoglobulin G (IgG), other cytokines, and bacterial or viral components. Likewise, the mode of action of TNF-α can be mediated by sTNF-RI and sTNF-RII, which prevent TNF-α from binding to membrane bound TNF-RI and/or TNF-RII.
Examples of inflammatory disorders treated by the methods of this technology include rheumatoid arthritis, osteoarthritis, osteolytis, tendonitis, synovitis, peripheral vascular disease, and inflammatory respiratory diseases (such as chronic obstructive pulmonary disease, fibrosis, emphysema, acute respiratory distress syndrome, and pneumonia). Treatment methods also include the prevention, reduction or elimination of pain associated with various disorders, such as pain associated with traumatic injury, muscle strain, arthritis (rheumatoid arthritis and osteoarthritis), synovitis, sacroiliac joint disorders, back disorders, post-surgical injections, tendon injections, sports medicine procedure (for example, ACL repair, MCL repair, BTB repair, patella repair, or cartilage repair), contusions, muscle strains, post traumatic osteoarthritis. Methods also include stimulation of chondrocyte production at the site of a collagen defect, such as defects at joints associated with arthritis, injuries or surgical procedures.
In some embodiments, methods of the present technology comprise administration of a Protein Solution to the site of a tissue defect to prevent or treat a disorder associated with IL-1ra. As referred to herein, such “tissue defects” include any condition involving tissue which is inadequate for physiological or cosmetic purposes. Examples of such defects include those that are congenital, those that result from or are symptomatic of disease, disorder, or trauma, and those that are consequent to surgical or other medical procedures. Embodiments include treatment for vascular, bone, skin, nerve, and organ tissue defects. Examples of such defects include those resulting from osteoporosis, spinal fixation procedures, hip and other joint replacement procedures, chronic wounds, fractures, sclerosis of tissues and muscles, and spinal cord or other nerve injury. In various embodiments, the compositions and methods of this invention may be used in methods associated with the repair bone or cartilage defects.
In various embodiments, methods are for the treatment of inflammatory disorders in a human. In other embodiments, treatment is for non-human mammals, such as companion, working, and sports animals. For example, such methods of this technology may be used for the treatment of inflammatory disorders in horses.
In various embodiments, methods of the present technology comprise a point-of-care method for making a Protein Solution. As referred to herein, a “point-of-care method” wherein the processes of the present technology are performed at a time proximate to the administration of the Protein Solution to the subject being treated. Such methods may be performed at a location proximate, such as in the same room (for example, bed side) or otherwise immediately adjacent, to the mammalian subject to be treated with the Protein Solution. In various embodiments, a “proximate time” may be, for example, within 12 hours, within 8 hours, within 2 hours, within 1 hour or within 30 minutes of administration of the Protein Solution to the subject.
In some embodiments, the Protein Solution is administered with a concomitant therapy. Such therapies include, for example, the administration of pharmaceutical actives or biologics, as described above. In some embodiments, concomitant therapies are administered concurrently with a Protein Solution. For example, methods may comprise administration of a Protein Solution with a safe and effective amount of an active selected from the group consisting of glucocorticosteroids, non-steroidal anti-inflammatories, antibiotics, antivirals, and combinations thereof.
In some embodiments, methods comprise administration of a Protein Solution with concentrated bone marrow aspirate, as described above. For example, cBMA and a Protein Solution may be administered concomitantly.
Methods of the present technology generally comprise administration of a Protein Solution to the site of inflammation in a mammalian subject. Administration of the Protein Solution can be performed with any suitable device, including such devices known in the art for topical delivery of compositions to the muscle, joint, vascular, lung or other tissue. For example, topical delivery for treatment of inflammation or pain associated with joint disorders may comprise injection of a Protein Solution at or near the joint. Treatment for inflammatory respiratory diseases may comprise delivery of a Protein Solution by endotracheal tubes, inhalers and nebulizers.
Embodiments of the present technology are further illustrated through the following non-limiting examples.
A Protein Solution rich in interleukin-I receptor antagonist is prepared from seven consented human providers. Blood (55 mL) is drawn into a 60 cc syringe with 5 mL of anticoagulant citrate dextrose solution A (ACD-A, Citra Labs, Braintree, Mass.). Platelet-rich plasma (PRP) is created using the GPS® III platelet concentration system (800-1 003A, Biomet Biologics, Warsaw, Ind.) according to the instructions for use. The solution is generated by adding 6 mL of PRP to a modified Plasmax device containing 1 gram of polyacrylamide beads (Biomet Biologics, Warsaw, Ind.). The IL-Ira solution is removed from the Plasmax devices and frozen at minus 50° C. for the assay. Cytokine content is assayed on a 16-plex ELISA (Searchlight® Protein Array ELISA system, Aushon Biosystems, Billerica, Mass.). The analytes included IL-4, IL-10, IL-11, IL-I3, IL-Ira, IFN-γ, sTNF-RI, sTNF-RII, IL-1α, IL-1β, TNF-α, IL-17, IL-18, bFGF, TBF-β1, and TBF-β2.
The solution contains both anabolic (bFGF, TGF-β1, TGF-β2 (see Table 3)) and anti-inflammatory (IL-1ra, sTNF-RI, sTNF-RII, IL-4, IL-10, IL-11, IL-13, IFN-γ, (see Table 4)) cytokines without expressing large doses of catabolic cytokines (IL-1α, IL-1β, TNF-α, IL-17, IL-18 (see Table 5)). The anti-inflammatory cytokines IL-Ira and sTNF-R are all detected in ng/mL quantities, while all of the catabolic analytes were in pg/mL quantities. However, donor-to-donor variability is detected. Correlations between the catabolic cytokines IL-1 and TNF-α and anti-inflammatory analytes IL-1ra and sTNF-R are compared, but no large correlations detected (Table 6). On average, there is about 13,260 times more IL-1ra than IL-1a and about 7,561 times more than IL-1β.
An IL-1ra-rich solution is created as follows. Whole blood (70 mL) anticoagulated (10%) with ACD-A (Braintree, Mass., USA) is drawn from 5 healthy volunteers. A portion (10 mL) is reserved for a whole blood measurement. Platelet-rich plasma (PRP) (6 mL) is produced using the GPS® II System (Biomet Biologics, LLC, Warsaw, Ind., USA). Complete blood counts are collected for the whole blood and PRP samples following a validated procedure, as described in Woodell-May J E, Ridderman D N, Swift M J, Higgins J. “Producing Accurate Platelet Counts for Platelet Rich Plasma: Validation of a Hematology Analyzer and Preparation Techniques for Counting” J. Craniofac. Surg. (2005) September 16(5):749-56.
Following the PRP production, 5 mL of the PRP is added to a modified plasma concentration device (Plasmax™, Biomet Biologics LLC, Warsaw, Ind., USA) and incubated with polyacrylamide desiccating beads in the device for 24 hours at room temperature. Following the contact with polyacrylamide beads the electromagnetic field, the plasma concentration device is centrifuged to separate the serum fraction.
To analyze baseline IL-1ra levels at time zero, the whole blood and PRP samples are activated with 50 μL of thrombin and 10% CaCl2 (1,000 units/mL). A blood clot is formed and incubated for 30 minutes at room temperature. Following incubation, the clot is centrifuged for 5 minutes at 3,000 rpm. Serum is collected from the clots and retained for ELISA analysis. The serum fraction from the plasma concentrator does not require activation by thrombin, and is tested directly. All samples are analyzed for IL-1ra using an ELISA kit (IL-1ra Quantikine™ Kit, R&D Systems, Minneapolis, Minn., USA).
The PRP samples result in about an eight-fold increase in platelets, about five-fold increase in total white blood cells (WBCs), about nine-fold increase in the monocyte fraction of the WBCs, and about a three-fold increase in the PMN fraction of the WBCs. The IL-1ra production in the whole blood and PRP samples is correlated most closely to the WBC concentration. The five-fold increase in the PRP is likely due to the increase in WBCs, and both the whole blood and PRP IL-1ra values can be considered baseline IL-1ra content. This is in contrast to the 195-fold increase in IL-1ra following incubation in the plasma concentrator. This plasma concentration device typically results in a 3-fold increase in plasma protein concentration due to a volume reduction caused by the desiccation process. This 3-fold decrease in volume does not account for the levels of increase seen in the amount of IL-1ra. Therefore, this level of increase indicates stimulation of WBCs to produce IL-1ra during the contact with the solid extraction material (e.g., polyacrylamide beads) and electromagnetic field stimulation.
Correlation analysis demonstrates that IL-1ra production is more closely correlated with the increase in WBCs than the platelet content. The IL-1ra levels do not correlate as closely with the WBC population in the PRP. This is not surprising since the WBC are not activated, and the serum is collected by thrombin activation of the plasma. However, it is possible that the WBC, once activated in the plasma concentration device, participate in the significant production of IL-1ra seen in this example.
Anticoagulated blood (120 cc) is collected from 5 human donors. Platelet-rich plasma (PRP) is prepared using GPS® III disposables (Biomet Biologics LLC, Warsaw, Ind., USA). PRP is loaded into modified plasma concentration devices (Plasmax™, Biomet Biologics LLC, Warsaw, Ind., USA) and processed. The output is divided into 4 groups: IL-1ra in concentrated plasma with and without thrombin activation (1000 U/mL in 1M CaC12), or cell-free IL-1ra with and without thrombin activation. IL-1ra is measured using ELISA (R&D Systems) over time.
The PRP contacts polyacrylamide beads in the Plasmax™ device while electromagnetic field stimulation is provided using a capacitively coupled electromagnetic field.
Unclotted PRP produces an average of about 50 ng over 24 hrs. The cell-free samples produce about 34 ng without changing over 24 hrs. Once clotted, the elution of IL-1ra is slowed, with only about 30% being eluted after 10 hours. Release in the cell-free samples is also delayed, but eluted 100% of available IL-1ra after 10 hours.
Protein Solutions from healthy patients are prepared as follows for the measurement of growth factors. 72 ml of anticoagulated whole blood are drawn by venipuncture from each of six donors. 3 ml of each donor's anticoagulated whole blood are aliquoted into microcentrifuge tubes and frozen at −50° C. 60 ml of the anticoagulated whole blood is loaded into GPS® III disposable devices (Biomet Biologics LLC, Warsaw, Ind., USA), which is processed according to the manufacturer's instructions to produce PRP. The PRP is removed from the GPS® III devices and added to Plasmax™ devices (Biomet Biologics LLC, Warsaw, Ind., USA), which is processed according to the manufacturer's instructions to produce APS. APS is extracted from each device, aliquoted into microcentrifuge tubes, and frozen at −50° C. Each sample, whole blood and PRP, is subjected to three freeze-thaw cycles. Quantikine Human Immunoassays (R&D Systems, Inc., Minneapolis, Minn.) for VEGF, PDGF-BB, PDGF-AB, EGF, TGF-β1, TGF-β2, and IGF-1 are run in duplicate according to the manufacturer's instructions for each APS and whole blood sample.
APS from healthy patients is prepared as above for the measurement of anti-inflammatory cytokines. Quantikine Human Immunoassays (R&D Systems, Inc., Minneapolis, Minn.) for IL-1ra, IL-1β, IL-8, sTNF-RI, TNF-α, IL-6, sTNF-RII, IL-10, IL-13, and IL-4 are run in duplicate according to the manufacturer's instructions for each APS and whole blood sample. Immunoassays are also performed to detect hepatocyte growth factor (HGF) and soluble IL-1RII.
APS from 105 osteoarthritis patients is prepared as above for the measurement of growth factors anti-inflammatory cytokines. The APS is stored at −50° C. or in dry ice.
Cytokine concentrations are compared between healthy donors and OA patients in baseline blood and APS. IL-1β is concentrated at a higher level in OA patients, but the fold increase is still much lower than that of IL-1ra. Other cytokines and growth factors that are concentrated at least to the level of that observed in healthy donors include sTNF-RI, IGF-I, IL-8, VEGF, and IL-6. The soluble cytokines sTNF-RII and sIL-1RII are concentrated to a level not quite as high but very similar to the healthy concentration level. The results are displayed in Table 7.
Adipose stromal cells are prepared as follows. Adipose tissue is minced into small pieces (about 1 cm3) and digested in 2 mg/mL type I collagenase (Worthington Biochemical Corp., Lakewood, N.J.) under intermittent mechanical agitation in a water bath at 37° C. for 180 minutes. Digestion can be neutralized by the addition of medium or a blood-derived solution. The cell suspension is centrifuged (300×g for 7 minutes at 25° C.) followed by removal of the supernatant from the cell pellet. The pellet is then re-suspended in a compatible solution to provide a liquid volume comprising Adipose stromal cells.
Alternatively, the pellet is suspended with whole blood obtained from the subject, and added to a GPS™ Platelet Concentrate System, from Biomet Biologics, Inc. (Warsaw, Ind.). Following centrifugation, the platelet-rich plasma layer, which also contains the adipose stromal cells, is extracted from the system.
The adipose stromal cells, optionally including platelet-rich plasma, are then combined with polyacrylamide beads to stimulate production of IL-1ra. The adipose stromal cells and polyacrylamide beads are separated from the liquid solution to obtain a solution rich in IL-1ra.
A therapeutic composition of IL-1ra is generated from stromal cells isolated from adipose tissue. Isolation of human stromal cells is performed by obtaining human subcutaneous adipose tissue from lipoaspiration/liposuction procedures and digesting the tissue in collagenase type I solution (Worthington Biochemical Corp., Lakewood, N.J.) under gentle agitation for 1 hour at 37° C. The dissociated cells are filtered with 500 μm and 250 μm Nitex filters. The fraction is centrifuged at 300×g for 5 minutes. The supernatant is discarded and the cell pellet is re-suspended in a compatible liquid solution, such as a blood-derived solution.
The headings (such as “Introduction” and “Summary”) and sub-headings used herein are intended only for general organization of topics within the present disclosure, and are not intended to limit the disclosure of the technology or any aspect thereof. In particular, subject matter disclosed in the “Introduction” may include novel technology and may not constitute a recitation of prior art. Subject matter disclosed in the “Summary” is not an exhaustive or complete disclosure of the entire scope of the technology or any embodiments thereof. Classification or discussion of a material within a section of this specification as having a particular utility is made for convenience, and no inference should be drawn that the material must necessarily or solely function in accordance with its classification herein when it is used in any given composition.
The disclosure of all patents and patent applications cited in this disclosure are incorporated by reference herein.
The description and specific examples, while indicating embodiments of the technology, are intended for purposes of illustration only and are not intended to limit the scope of the technology. Equivalent changes, modifications and variations of specific embodiments, materials, compositions and methods may be made within the scope of the present technology, with substantially similar results. Moreover, recitation of multiple embodiments having stated features is not intended to exclude other embodiments having additional features, or other embodiments incorporating different combinations of the stated features. Specific examples are provided for illustrative purposes of how to make and use the compositions and methods of this technology and, unless explicitly stated otherwise, are not intended to be a representation that given embodiments of this technology have, or have not, been made or tested.
As used herein, the words “prefer” or “preferable” refer to embodiments of the technology that afford certain benefits, under certain circumstances. However, other embodiments may also be preferred, under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the technology.
As used herein, the word “include,” and its variants, is intended to be non-limiting, such that recitation of items in a list is not to the exclusion of other like items that may also be useful in the materials, compositions, devices, and methods of this technology. Similarly, the terms “can” and “may” and their variants are intended to be non-limiting, such that recitation that an embodiment can or may comprise certain elements or features does not exclude other embodiments of the present technology that do not contain those elements or features.
Although the open-ended term “comprising,” as a synonym of non-restrictive terms such as including, containing, or having, is used herein to describe and claim embodiments of the present technology, embodiments may alternatively be described using more limiting terms such as “consisting of” or “consisting essentially of.” Thus, for any given embodiment reciting materials, components or process steps, the present technology also specifically includes embodiments consisting of, or consisting essentially of, such materials, components or processes excluding additional materials, components or processes (for consisting of) and excluding additional materials, components or processes affecting the significant properties of the embodiment (for consisting essentially of), even though such additional materials, components or processes are not explicitly recited in this application. For example, recitation of a composition or process reciting elements A, B and C specifically envisions embodiments consisting of, and consisting essentially of, A, B and C, excluding an element D that may be recited in the art, even though element D is not explicitly described as being excluded herein. Further, as used herein the term “consisting essentially of” recited materials or components envisions embodiments “consisting of” the recited materials or components.
A” and “an” as used herein indicate “at least one” of the item is present; a plurality of such items may be present, when possible. “About” when applied to values indicates that the calculation or the measurement allows some slight imprecision in the value (with some approach to exactness in the value; approximately or reasonably close to the value; nearly). If, for some reason, the imprecision provided by “about” is not otherwise understood in the art with this ordinary meaning, then “about” as used herein indicates at least variations that may arise from ordinary methods of measuring or using such parameters.
As referred to herein, ranges are, unless specified otherwise, inclusive of endpoints and include disclosure of all distinct values and further divided ranges within the entire range. Thus, for example, a range of “from A to B” or “from about A to about B” is inclusive of A and of B. Disclosure of values and ranges of values for specific parameters (such as temperatures, molecular weights, weight percentages, etc.) are not exclusive of other values and ranges of values useful herein. It is envisioned that two or more specific exemplified values for a given parameter may define endpoints for a range of values that may be claimed for the parameter. For example, if Parameter X is exemplified herein to have value A and also exemplified to have value Z, it is envisioned that Parameter X may have a range of values from about A to about Z. Similarly, it is envisioned that disclosure of two or more ranges of values for a parameter (whether such ranges are nested, overlapping or distinct) subsume all possible combination of ranges for the value that might be claimed using endpoints of the disclosed ranges. For example, if Parameter X is exemplified herein to have values in the range of 1-10, or 2-9, or 3-8, it is also envisioned that Parameter X may have other ranges of values including 1-9, 1-8, 1-3, 1-2, 2-10, 2-8, 2-3, 3-10, and 3-9.
| Number | Name | Date | Kind |
|---|---|---|---|
| 593333 | Park | Nov 1897 | A |
| 1468313 | Fritz | Sep 1923 | A |
| 1593814 | Robert | Jul 1926 | A |
| 2722257 | Lockhart | Nov 1955 | A |
| 3013557 | Pallotta | Dec 1961 | A |
| 3141846 | Laven, Jr. | Jul 1964 | A |
| 3159159 | Cohen | Dec 1964 | A |
| 3300051 | Mitchell | Jan 1967 | A |
| 3409165 | Creith | Nov 1968 | A |
| 3420374 | Umeda | Jan 1969 | A |
| 3441143 | Kudlaty | Apr 1969 | A |
| 3453364 | Flodin et al. | Jul 1969 | A |
| 3469369 | Helmke | Sep 1969 | A |
| 3508653 | Coleman | Apr 1970 | A |
| 3545671 | Ross | Dec 1970 | A |
| 3583627 | Wilson | Jun 1971 | A |
| 3596652 | Winkelman | Aug 1971 | A |
| 3647070 | Adler | Mar 1972 | A |
| 3654925 | Holderith | Apr 1972 | A |
| 3661265 | Greenspan | May 1972 | A |
| 3706305 | Berger et al. | Dec 1972 | A |
| 3706306 | Berger et al. | Dec 1972 | A |
| 3723244 | Breillatt | Mar 1973 | A |
| 3741400 | Dick | Jun 1973 | A |
| 3779383 | Ayres | Dec 1973 | A |
| 3785549 | Latham | Jan 1974 | A |
| 3814248 | Lawhead | Jun 1974 | A |
| 3849072 | Ayres | Nov 1974 | A |
| 3850369 | Bull et al. | Nov 1974 | A |
| 3879295 | Glover et al. | Apr 1975 | A |
| 3887466 | Ayres | Jun 1975 | A |
| 3894952 | Ayres | Jul 1975 | A |
| 3896733 | Rosenberg | Jul 1975 | A |
| 3897337 | Ayres | Jul 1975 | A |
| 3897343 | Ayres | Jul 1975 | A |
| 3909419 | Ayres | Sep 1975 | A |
| 3929646 | Adler | Dec 1975 | A |
| 3931010 | Ayres et al. | Jan 1976 | A |
| 3931018 | North, Jr. | Jan 1976 | A |
| 3935113 | Ayres | Jan 1976 | A |
| 3937211 | Merten | Feb 1976 | A |
| 3941699 | Ayres | Mar 1976 | A |
| 3945928 | Ayres | Mar 1976 | A |
| 3951801 | Ayres | Apr 1976 | A |
| 3957654 | Ayres | May 1976 | A |
| 3962085 | Liston et al. | Jun 1976 | A |
| 3965889 | Sachs | Jun 1976 | A |
| 3972812 | Gresl, Jr. | Aug 1976 | A |
| 3982691 | Schlutz | Sep 1976 | A |
| 4001122 | Griffin | Jan 1977 | A |
| 4020831 | Adler | May 1977 | A |
| 4046699 | Zine, Jr. | Sep 1977 | A |
| 4055501 | Cornell | Oct 1977 | A |
| 4059108 | Latham, Jr. | Nov 1977 | A |
| 4066549 | Oeser et al. | Jan 1978 | A |
| 4077396 | Wardlaw et al. | Mar 1978 | A |
| 4088582 | Murty | May 1978 | A |
| 4146172 | Cullis et al. | Mar 1979 | A |
| 4152270 | Cornell | May 1979 | A |
| 4154690 | Ballies | May 1979 | A |
| 4159896 | Levine et al. | Jul 1979 | A |
| 4187979 | Cullis et al. | Feb 1980 | A |
| 4189385 | Greenspan | Feb 1980 | A |
| 4203840 | Stoeppler et al. | May 1980 | A |
| 4204537 | Latham, Jr. | May 1980 | A |
| 4225580 | Rothman et al. | Sep 1980 | A |
| 4229298 | Bange | Oct 1980 | A |
| 4269718 | Persidsky | May 1981 | A |
| 4294707 | Ikeda et al. | Oct 1981 | A |
| 4298598 | Schwarz et al. | Nov 1981 | A |
| 4300717 | Latham, Jr. | Nov 1981 | A |
| 4303193 | Latham, Jr. | Dec 1981 | A |
| 4314823 | Rich, Jr. | Feb 1982 | A |
| 4322298 | Persidsky | Mar 1982 | A |
| 4332351 | Kellogg | Jun 1982 | A |
| 4362567 | Schwarz et al. | Dec 1982 | A |
| 4364832 | Ballies | Dec 1982 | A |
| 4377572 | Schwarz et al. | Mar 1983 | A |
| 4379849 | Heimreid | Apr 1983 | A |
| 4411794 | Schwinn et al. | Oct 1983 | A |
| 4414976 | Schwarz et al. | Nov 1983 | A |
| 4416654 | Schoendorfer | Nov 1983 | A |
| 4417981 | Nugent | Nov 1983 | A |
| 4424132 | Iriguchi | Jan 1984 | A |
| 4427650 | Stroetmann | Jan 1984 | A |
| 4427651 | Stroetmann | Jan 1984 | A |
| 4442655 | Stroetmann | Apr 1984 | A |
| 4443345 | Wells | Apr 1984 | A |
| 4445550 | Davis et al. | May 1984 | A |
| 4446021 | Aufderhaar et al. | May 1984 | A |
| 4453927 | Sinko | Jun 1984 | A |
| 4453939 | Zimmerman et al. | Jun 1984 | A |
| 4464167 | Schoendorfer | Aug 1984 | A |
| 4511662 | Baran et al. | Apr 1985 | A |
| 4537767 | Rothman et al. | Aug 1985 | A |
| RE32089 | Blatt et al. | Mar 1986 | E |
| 4577514 | Bradley et al. | Mar 1986 | A |
| 4610656 | Mortensen | Sep 1986 | A |
| 4617009 | Ohlin | Oct 1986 | A |
| 4627879 | Rose et al. | Dec 1986 | A |
| 4631055 | Redl et al. | Dec 1986 | A |
| 4632761 | Bowers | Dec 1986 | A |
| 4639316 | Eldegheidy | Jan 1987 | A |
| 4650678 | Fuhge et al. | Mar 1987 | A |
| 4655211 | Sakamoto et al. | Apr 1987 | A |
| 4672969 | Dew | Jun 1987 | A |
| 4675117 | Neumann et al. | Jun 1987 | A |
| 4680025 | Kruger | Jul 1987 | A |
| 4708799 | Gerlach et al. | Nov 1987 | A |
| 4714457 | Alterbaum | Dec 1987 | A |
| 4722790 | Cawley et al. | Feb 1988 | A |
| 4724317 | Brown | Feb 1988 | A |
| 4735616 | Eibl et al. | Apr 1988 | A |
| 4735726 | Duggins | Apr 1988 | A |
| 4738655 | Brimhall et al. | Apr 1988 | A |
| 4755300 | Fischel et al. | Jul 1988 | A |
| 4755301 | Bowers | Jul 1988 | A |
| 4770779 | Ichikawa et al. | Sep 1988 | A |
| 4776964 | Schoendorfer et al. | Oct 1988 | A |
| 4818291 | Iwatsuki et al. | Apr 1989 | A |
| 4818386 | Burns | Apr 1989 | A |
| 4828710 | Itoh et al. | May 1989 | A |
| 4832851 | Bowers | May 1989 | A |
| 4834890 | Brown et al. | May 1989 | A |
| 4839058 | Cawley et al. | Jun 1989 | A |
| 4844818 | Smith | Jul 1989 | A |
| 4846780 | Galloway et al. | Jul 1989 | A |
| 4846835 | Grande | Jul 1989 | A |
| 4850952 | Figdor et al. | Jul 1989 | A |
| 4853137 | Ersson | Aug 1989 | A |
| 4871462 | Fischel et al. | Oct 1989 | A |
| 4874368 | Miller et al. | Oct 1989 | A |
| 4877520 | Burns | Oct 1989 | A |
| 4879031 | Panzani | Nov 1989 | A |
| 4900453 | Sedlmayer | Feb 1990 | A |
| 4902281 | Avoy | Feb 1990 | A |
| 4909251 | Seelich | Mar 1990 | A |
| 4915847 | Dillon et al. | Apr 1990 | A |
| 4917801 | Luderer et al. | Apr 1990 | A |
| 4928603 | Rose et al. | May 1990 | A |
| 4929242 | Desecki et al. | May 1990 | A |
| 4933291 | Daiss et al. | Jun 1990 | A |
| 4939081 | Figdor et al. | Jul 1990 | A |
| 4943273 | Pages | Jul 1990 | A |
| 4946601 | Fiehler | Aug 1990 | A |
| 4950220 | Wells et al. | Aug 1990 | A |
| 4957637 | Cornell | Sep 1990 | A |
| 4957638 | Smith | Sep 1990 | A |
| 4973168 | Chan | Nov 1990 | A |
| 4983157 | Pober et al. | Jan 1991 | A |
| 4983158 | Headley | Jan 1991 | A |
| 4985153 | Kuroda et al. | Jan 1991 | A |
| 5000970 | Shanbhag et al. | Mar 1991 | A |
| 5002571 | O'donnell, Jr. | Mar 1991 | A |
| 5019243 | McEwen et al. | May 1991 | A |
| 5024613 | Vasconcellos et al. | Jun 1991 | A |
| 5030215 | Morse et al. | Jul 1991 | A |
| 5030341 | McEwen et al. | Jul 1991 | A |
| 5039401 | Columbus et al. | Aug 1991 | A |
| 5045048 | Kaleskas | Sep 1991 | A |
| 5047004 | Wells | Sep 1991 | A |
| 5053127 | Schoendorfer et al. | Oct 1991 | A |
| 5053134 | Luderer et al. | Oct 1991 | A |
| 5071570 | Shiraki et al. | Dec 1991 | A |
| 5075222 | Hannum et al. | Dec 1991 | A |
| 5080262 | Herold et al. | Jan 1992 | A |
| 5086784 | Levine et al. | Feb 1992 | A |
| 5100564 | Pall et al. | Mar 1992 | A |
| 5104375 | Wolf et al. | Apr 1992 | A |
| 5112484 | Zuk, Jr. | May 1992 | A |
| 5112490 | Turpen | May 1992 | A |
| 5131907 | Williams et al. | Jul 1992 | A |
| 5137832 | Levine et al. | Aug 1992 | A |
| 5141645 | Shiraki et al. | Aug 1992 | A |
| 5147290 | Jonsson | Sep 1992 | A |
| 5152905 | Pall et al. | Oct 1992 | A |
| 5156613 | Sawyer | Oct 1992 | A |
| 5165938 | Knighton | Nov 1992 | A |
| 5171456 | Hwang et al. | Dec 1992 | A |
| 5173295 | Wehling | Dec 1992 | A |
| 5178602 | Wells | Jan 1993 | A |
| 5185001 | Galanakis | Feb 1993 | A |
| 5188583 | Guigan | Feb 1993 | A |
| 5190057 | Sarfarazi | Mar 1993 | A |
| 5190759 | Lindblad et al. | Mar 1993 | A |
| 5197985 | Caplan | Mar 1993 | A |
| 5203825 | Haynes | Apr 1993 | A |
| 5204537 | Bennet et al. | Apr 1993 | A |
| 5206023 | Hunziker | Apr 1993 | A |
| 5207638 | Choksi et al. | May 1993 | A |
| 5217426 | Bacehowski et al. | Jun 1993 | A |
| 5217627 | Pall et al. | Jun 1993 | A |
| 5219328 | Morse et al. | Jun 1993 | A |
| 5226877 | Epstein | Jul 1993 | A |
| 5226914 | Caplan et al. | Jul 1993 | A |
| 5234608 | Duff | Aug 1993 | A |
| 5236604 | Fiehler | Aug 1993 | A |
| 5251786 | Sarrine | Oct 1993 | A |
| 5258126 | Pall et al. | Nov 1993 | A |
| 5260420 | Burnouf-radosevich et al. | Nov 1993 | A |
| 5269927 | Fiehler | Dec 1993 | A |
| 5271852 | Luoma, II | Dec 1993 | A |
| 5279825 | Wehling | Jan 1994 | A |
| 5281342 | Biesel et al. | Jan 1994 | A |
| 5290552 | Sierra et al. | Mar 1994 | A |
| 5290918 | Bui-khac | Mar 1994 | A |
| 5298171 | Biesel | Mar 1994 | A |
| 5304372 | Michalski et al. | Apr 1994 | A |
| 5316674 | Pall et al. | May 1994 | A |
| 5318524 | Morse et al. | Jun 1994 | A |
| 5318782 | Weis-fogh | Jun 1994 | A |
| 5321126 | Van Dommelen et al. | Jun 1994 | A |
| 5322620 | Brown et al. | Jun 1994 | A |
| 5330974 | Pines et al. | Jul 1994 | A |
| 5344752 | Murphy | Sep 1994 | A |
| 5354483 | Furse | Oct 1994 | A |
| 5359032 | Dayer et al. | Oct 1994 | A |
| 5370221 | Magnusson et al. | Dec 1994 | A |
| 5370802 | Brown | Dec 1994 | A |
| 5372945 | Alchas et al. | Dec 1994 | A |
| 5376263 | Fischel | Dec 1994 | A |
| 5387187 | Fell et al. | Feb 1995 | A |
| 5393674 | Levine et al. | Feb 1995 | A |
| 5395923 | Bui-khac et al. | Mar 1995 | A |
| 5403272 | Deniega et al. | Apr 1995 | A |
| 5405607 | Epstein | Apr 1995 | A |
| 5409833 | Hu et al. | Apr 1995 | A |
| 5411885 | Marx | May 1995 | A |
| 5417650 | Gordon | May 1995 | A |
| 5420250 | Lontz | May 1995 | A |
| 5443481 | Lee | Aug 1995 | A |
| 5454958 | Fiehler | Oct 1995 | A |
| 5456693 | Conston et al. | Oct 1995 | A |
| 5456885 | Coleman et al. | Oct 1995 | A |
| 5474687 | Van Vlasselaer | Dec 1995 | A |
| 5480378 | Weis-fogh et al. | Jan 1996 | A |
| 5484383 | Fitch, Jr. et al. | Jan 1996 | A |
| 5486359 | Caplan et al. | Jan 1996 | A |
| 5494578 | Brown | Feb 1996 | A |
| 5494592 | Latham, Jr. et al. | Feb 1996 | A |
| 5501371 | Schwartz-feldman | Mar 1996 | A |
| 5505685 | Antwiler | Apr 1996 | A |
| 5510102 | Cochrum | Apr 1996 | A |
| 5520885 | Coelho et al. | May 1996 | A |
| 5525477 | Hassouna | Jun 1996 | A |
| 5533518 | Vogler | Jul 1996 | A |
| 5560830 | Coleman et al. | Oct 1996 | A |
| 5571418 | Lee et al. | Nov 1996 | A |
| 5575778 | Hardt et al. | Nov 1996 | A |
| 5577513 | Van Vlasselaer | Nov 1996 | A |
| 5585007 | Antanavich et al. | Dec 1996 | A |
| 5588958 | Cunningham et al. | Dec 1996 | A |
| 5589462 | Patat et al. | Dec 1996 | A |
| 5599558 | Gordinier et al. | Feb 1997 | A |
| 5601711 | Sklar et al. | Feb 1997 | A |
| 5601727 | Bormann et al. | Feb 1997 | A |
| 5603845 | Holm | Feb 1997 | A |
| 5607579 | Latham, Jr. et al. | Mar 1997 | A |
| 5614106 | Payrat et al. | Mar 1997 | A |
| 5618663 | Delmas | Apr 1997 | A |
| 5632895 | Tsukagoshi et al. | May 1997 | A |
| 5632905 | Haynes | May 1997 | A |
| 5641414 | Brown | Jun 1997 | A |
| 5641622 | Lake et al. | Jun 1997 | A |
| 5643192 | Hirsh | Jul 1997 | A |
| 5643193 | Papillon et al. | Jul 1997 | A |
| 5645540 | Henniges et al. | Jul 1997 | A |
| 5646004 | Van Vlasselaer | Jul 1997 | A |
| 5648223 | Van Vlasselaer | Jul 1997 | A |
| 5649903 | Deniega et al. | Jul 1997 | A |
| 5663051 | Vlasselaer | Sep 1997 | A |
| 5674173 | Hlavinka et al. | Oct 1997 | A |
| 5707331 | Wells et al. | Jan 1998 | A |
| 5707647 | Dunn et al. | Jan 1998 | A |
| 5707876 | Levine | Jan 1998 | A |
| 5716616 | Prockop et al. | Feb 1998 | A |
| 5723331 | Tubo et al. | Mar 1998 | A |
| 5724988 | Dennehey et al. | Mar 1998 | A |
| 5733466 | Benebo et al. | Mar 1998 | A |
| 5733545 | Hood, III | Mar 1998 | A |
| 5736033 | Coleman et al. | Apr 1998 | A |
| 5738784 | Holm et al. | Apr 1998 | A |
| 5738796 | Bormann et al. | Apr 1998 | A |
| 5750025 | Holmes et al. | May 1998 | A |
| 5750658 | Coelho et al. | May 1998 | A |
| 5762798 | Wenthold et al. | Jun 1998 | A |
| 5785700 | Olson | Jul 1998 | A |
| 5786217 | Tubo et al. | Jul 1998 | A |
| 5788662 | Antanavich et al. | Aug 1998 | A |
| 5792344 | Holm | Aug 1998 | A |
| 5792450 | Wilson et al. | Aug 1998 | A |
| 5795489 | Holm | Aug 1998 | A |
| 5795571 | Cederholm-Williams et al. | Aug 1998 | A |
| 5795751 | Apel | Aug 1998 | A |
| 5811094 | Caplan et al. | Sep 1998 | A |
| 5811151 | Hendriks et al. | Sep 1998 | A |
| 5817519 | Zelmanovic et al. | Oct 1998 | A |
| 5823986 | Peterson | Oct 1998 | A |
| 5824084 | Muschler | Oct 1998 | A |
| 5830359 | Knight et al. | Nov 1998 | A |
| 5833866 | Brown | Nov 1998 | A |
| 5834418 | Brazeau et al. | Nov 1998 | A |
| 5837150 | Langley et al. | Nov 1998 | A |
| 5840502 | Van Vlasselaer | Nov 1998 | A |
| 5842477 | Naughton et al. | Dec 1998 | A |
| 5846427 | Kessler et al. | Dec 1998 | A |
| 5853600 | McNeal et al. | Dec 1998 | A |
| 5860937 | Cohen | Jan 1999 | A |
| 5863892 | Stern et al. | Jan 1999 | A |
| 5865785 | Bischof | Feb 1999 | A |
| 5885239 | Headley et al. | Mar 1999 | A |
| 5889584 | Wardlaw | Mar 1999 | A |
| 5895346 | Wells et al. | Apr 1999 | A |
| 5899874 | Jonsson | May 1999 | A |
| 5900245 | Sawhney et al. | May 1999 | A |
| 5906934 | Grande et al. | May 1999 | A |
| 5916557 | Berlowitz-tarrant et al. | Jun 1999 | A |
| 5916743 | Lake et al. | Jun 1999 | A |
| 5918622 | Perez | Jul 1999 | A |
| 5924972 | Turvaville et al. | Jul 1999 | A |
| 5934803 | Hutter | Aug 1999 | A |
| 5938621 | Kelly et al. | Aug 1999 | A |
| 5951160 | Ronk | Sep 1999 | A |
| 5955032 | Kelly et al. | Sep 1999 | A |
| 5955436 | Kunkle, Jr. | Sep 1999 | A |
| 5958250 | Brown et al. | Sep 1999 | A |
| 5958253 | Holm | Sep 1999 | A |
| 5961210 | McCardel et al. | Oct 1999 | A |
| 5980734 | Itoh | Nov 1999 | A |
| 5980757 | Brown et al. | Nov 1999 | A |
| 5985315 | Patat et al. | Nov 1999 | A |
| 5997544 | Nies et al. | Dec 1999 | A |
| 6007811 | Sawyer et al. | Dec 1999 | A |
| 6010627 | Hood, III | Jan 2000 | A |
| 6011490 | Tonnesen et al. | Jan 2000 | A |
| 6020196 | Hu et al. | Feb 2000 | A |
| 6022306 | Dumont et al. | Feb 2000 | A |
| 6025201 | Zelmanovic et al. | Feb 2000 | A |
| 6027655 | Holm | Feb 2000 | A |
| 6049026 | Muschler | Apr 2000 | A |
| 6051146 | Green et al. | Apr 2000 | A |
| 6051147 | Bischof | Apr 2000 | A |
| 6053856 | Hlavinka | Apr 2000 | A |
| 6054122 | MacPhee et al. | Apr 2000 | A |
| 6063297 | Antanavich et al. | May 2000 | A |
| 6063624 | Kandler et al. | May 2000 | A |
| 6071421 | Brown | Jun 2000 | A |
| 6071422 | Hlavinka et al. | Jun 2000 | A |
| 6071423 | Brown et al. | Jun 2000 | A |
| 6090793 | Zimmermann et al. | Jul 2000 | A |
| 6096309 | Prior et al. | Aug 2000 | A |
| 6096728 | Collins et al. | Aug 2000 | A |
| 6102843 | Kelley et al. | Aug 2000 | A |
| 6117425 | MacPhee et al. | Sep 2000 | A |
| 6123655 | Fell | Sep 2000 | A |
| 6150163 | McPherson et al. | Nov 2000 | A |
| 6153113 | Goodrich et al. | Nov 2000 | A |
| 6183737 | Zaleske et al. | Feb 2001 | B1 |
| 6196987 | Holmes et al. | Mar 2001 | B1 |
| 6197325 | MacPhee et al. | Mar 2001 | B1 |
| 6200287 | Keller et al. | Mar 2001 | B1 |
| 6200606 | Peterson et al. | Mar 2001 | B1 |
| 6214338 | Antanavich et al. | Apr 2001 | B1 |
| 6221315 | Giesler et al. | Apr 2001 | B1 |
| 6245900 | Yamasaki et al. | Jun 2001 | B1 |
| 6264890 | Boehringer et al. | Jul 2001 | B1 |
| 6274090 | Coelho et al. | Aug 2001 | B1 |
| 6277961 | Hock et al. | Aug 2001 | B1 |
| 6280400 | Niermann | Aug 2001 | B1 |
| 6286670 | Smith | Sep 2001 | B1 |
| 6287558 | Lanza et al. | Sep 2001 | B1 |
| 6296602 | Headley | Oct 2001 | B1 |
| 6316247 | Katz et al. | Nov 2001 | B1 |
| 6322785 | Landesberg et al. | Nov 2001 | B1 |
| 6327491 | Franklin et al. | Dec 2001 | B1 |
| 6328765 | Hardwick et al. | Dec 2001 | B1 |
| 6334842 | Hlavinka et al. | Jan 2002 | B1 |
| 6337072 | Ford et al. | Jan 2002 | B1 |
| 6342157 | Hood, III | Jan 2002 | B1 |
| 6351659 | Vilsmeier | Feb 2002 | B1 |
| 6355239 | Bruder et al. | Mar 2002 | B1 |
| 6368298 | Beretta et al. | Apr 2002 | B1 |
| 6368498 | Guilmette | Apr 2002 | B1 |
| 6398972 | Blasetti et al. | Jun 2002 | B1 |
| 6406671 | Dicesare et al. | Jun 2002 | B1 |
| 6409528 | Bodnar | Jun 2002 | B1 |
| 6410344 | Chung | Jun 2002 | B1 |
| 6417004 | Brady et al. | Jul 2002 | B1 |
| 6440444 | Boyce et al. | Aug 2002 | B2 |
| 6444228 | Baugh et al. | Sep 2002 | B1 |
| 6464624 | Pages | Oct 2002 | B2 |
| 6471069 | Lin et al. | Oct 2002 | B2 |
| 6472162 | Coelho et al. | Oct 2002 | B1 |
| 6487992 | Hollis | Dec 2002 | B1 |
| 6508778 | Verkaart et al. | Jan 2003 | B1 |
| 6516953 | Dicesare et al. | Feb 2003 | B1 |
| 6523698 | Dennehey et al. | Feb 2003 | B1 |
| 6544162 | Van et al. | Apr 2003 | B1 |
| 6544727 | Hei | Apr 2003 | B1 |
| 6558341 | Swisher | May 2003 | B1 |
| 6563953 | Lin et al. | May 2003 | B2 |
| 6596180 | Baugh et al. | Jul 2003 | B2 |
| 6599873 | Sommer et al. | Jul 2003 | B1 |
| 6623472 | Reincke et al. | Sep 2003 | B1 |
| 6623959 | Harris | Sep 2003 | B2 |
| 6629919 | Egozy et al. | Oct 2003 | B2 |
| 6638503 | Chitte | Oct 2003 | B2 |
| 6649072 | Brandt et al. | Nov 2003 | B2 |
| 6676629 | Andrew et al. | Jan 2004 | B2 |
| 6713246 | Reinecke et al. | Mar 2004 | B1 |
| 6716187 | Jorgensen | Apr 2004 | B1 |
| 6719901 | Dolecek et al. | Apr 2004 | B2 |
| 6733471 | Ericson et al. | May 2004 | B1 |
| 6758978 | Bedell | Jul 2004 | B1 |
| 6759188 | Reinecke et al. | Jul 2004 | B2 |
| 6764531 | Hogan | Jul 2004 | B2 |
| 6777231 | Katz et al. | Aug 2004 | B1 |
| 6790371 | Dolecek | Sep 2004 | B2 |
| 6803022 | Dicesare et al. | Oct 2004 | B2 |
| 6811777 | Mishra | Nov 2004 | B2 |
| 6830762 | Baugh et al. | Dec 2004 | B2 |
| 6835353 | Smith et al. | Dec 2004 | B2 |
| 6835377 | Goldberg et al. | Dec 2004 | B2 |
| RE38730 | Jakary et al. | Apr 2005 | E |
| 6899813 | Dolecek et al. | May 2005 | B2 |
| 6905612 | Dorian et al. | Jun 2005 | B2 |
| 6911202 | Amir et al. | Jun 2005 | B2 |
| RE38757 | Jakary et al. | Jul 2005 | E |
| 6979307 | Beretta et al. | Dec 2005 | B2 |
| 7011644 | Andrew et al. | Mar 2006 | B1 |
| 7011852 | Sukavaneshvar et al. | Mar 2006 | B2 |
| 7077273 | Ellsworth et al. | Jul 2006 | B2 |
| 7077827 | Greenfield | Jul 2006 | B2 |
| 7155288 | Soykan et al. | Dec 2006 | B2 |
| 7166283 | Tsuji et al. | Jan 2007 | B2 |
| 7179391 | Leach et al. | Feb 2007 | B2 |
| 7195606 | Ballin | Mar 2007 | B2 |
| 7223346 | Dorian et al. | May 2007 | B2 |
| 7273886 | Olivero | Sep 2007 | B2 |
| 7354515 | Coull et al. | Apr 2008 | B2 |
| 7374678 | Leach et al. | May 2008 | B2 |
| 7411006 | Shanbrom | Aug 2008 | B2 |
| 7465293 | Reinecke et al. | Dec 2008 | B2 |
| 7470371 | Dorian et al. | Dec 2008 | B2 |
| 7531355 | Rodríguez et al. | May 2009 | B2 |
| 7553413 | Dorian et al. | Jun 2009 | B2 |
| 7608258 | Mishra | Oct 2009 | B2 |
| 7678385 | Reddi | Mar 2010 | B2 |
| 7694828 | Swift et al. | Apr 2010 | B2 |
| 7708152 | Dorian et al. | May 2010 | B2 |
| 7806276 | Leach et al. | Oct 2010 | B2 |
| 7845499 | Higgins et al. | Dec 2010 | B2 |
| 7867765 | Faustman et al. | Jan 2011 | B2 |
| 7901344 | Yoo | Mar 2011 | B2 |
| 7901584 | Dorian et al. | Mar 2011 | B2 |
| 7914689 | Higgins et al. | Mar 2011 | B2 |
| 7987995 | Dorian et al. | Aug 2011 | B2 |
| 7992725 | Leach et al. | Aug 2011 | B2 |
| 8048297 | Leach et al. | Nov 2011 | B2 |
| 8048321 | Leach et al. | Nov 2011 | B2 |
| 8062534 | Higgins et al. | Nov 2011 | B2 |
| 8067534 | Jagota | Nov 2011 | B2 |
| 8202539 | Behnam et al. | Jun 2012 | B2 |
| 8567609 | Landrigan et al. | Oct 2013 | B2 |
| 8596470 | Leach et al. | Dec 2013 | B2 |
| 8753690 | Higgins et al. | Jun 2014 | B2 |
| 8783470 | Hecker et al. | Jul 2014 | B2 |
| 8801586 | Dorian et al. | Aug 2014 | B2 |
| 8808551 | Leach et al. | Aug 2014 | B2 |
| 8950586 | Dorian et al. | Feb 2015 | B2 |
| 8992862 | Leach et al. | Mar 2015 | B2 |
| 9011800 | Leach et al. | Apr 2015 | B2 |
| 9556243 | Leach et al. | Jan 2017 | B2 |
| 20010009757 | Bischof et al. | Jul 2001 | A1 |
| 20010053764 | Sims et al. | Dec 2001 | A1 |
| 20020009454 | Boone et al. | Jan 2002 | A1 |
| 20020032112 | Pages | Mar 2002 | A1 |
| 20020035820 | Farris | Mar 2002 | A1 |
| 20020076400 | Katz et al. | Jun 2002 | A1 |
| 20020077276 | Fredeking et al. | Jun 2002 | A1 |
| 20020082220 | Hoemann et al. | Jun 2002 | A1 |
| 20020090711 | Karlsson | Jul 2002 | A1 |
| 20020104808 | Blasetti et al. | Aug 2002 | A1 |
| 20020114775 | Pathak | Aug 2002 | A1 |
| 20020119179 | Rezania et al. | Aug 2002 | A1 |
| 20020161449 | Muschler | Oct 2002 | A1 |
| 20020169408 | Beretta et al. | Nov 2002 | A1 |
| 20020172666 | Sacchi et al. | Nov 2002 | A1 |
| 20020182664 | Dolecek et al. | Dec 2002 | A1 |
| 20020192632 | Hei et al. | Dec 2002 | A1 |
| 20030033021 | Plouhar et al. | Feb 2003 | A1 |
| 20030033022 | Plouhar et al. | Feb 2003 | A1 |
| 20030050709 | Noth et al. | Mar 2003 | A1 |
| 20030050710 | Petersen et al. | Mar 2003 | A1 |
| 20030055511 | Schryver et al. | Mar 2003 | A1 |
| 20030082152 | Hedrick et al. | May 2003 | A1 |
| 20030091536 | Frisbie et al. | May 2003 | A1 |
| 20030099650 | Ho et al. | May 2003 | A1 |
| 20030138910 | Reinecke et al. | Jul 2003 | A1 |
| 20030185803 | Kadiyala et al. | Oct 2003 | A1 |
| 20030191429 | Andrew et al. | Oct 2003 | A1 |
| 20030194397 | Mishra | Oct 2003 | A1 |
| 20030198687 | Bennett | Oct 2003 | A1 |
| 20030205538 | Dorian et al. | Nov 2003 | A1 |
| 20040005246 | Efthimiadis et al. | Jan 2004 | A1 |
| 20040013575 | Stevens et al. | Jan 2004 | A1 |
| 20040120942 | McGinnis et al. | Jun 2004 | A1 |
| 20040171146 | Katz et al. | Sep 2004 | A1 |
| 20040182395 | Brookman | Sep 2004 | A1 |
| 20040182788 | Dorian et al. | Sep 2004 | A1 |
| 20040182795 | Dorian et al. | Sep 2004 | A1 |
| 20040219182 | Gomes et al. | Nov 2004 | A1 |
| 20040251217 | Leach et al. | Dec 2004 | A1 |
| 20040258671 | Watkins | Dec 2004 | A1 |
| 20050059589 | Mullarkey | Mar 2005 | A1 |
| 20050076396 | Katz et al. | Apr 2005 | A1 |
| 20050084961 | Hedrick et al. | Apr 2005 | A1 |
| 20050084962 | Simon | Apr 2005 | A1 |
| 20050100536 | Mishra | May 2005 | A1 |
| 20050109716 | Leach et al. | May 2005 | A1 |
| 20050130301 | McKay et al. | Jun 2005 | A1 |
| 20050145187 | Gray | Jul 2005 | A1 |
| 20050152905 | Omoigui | Jul 2005 | A1 |
| 20050153441 | Hedrick et al. | Jul 2005 | A1 |
| 20050153442 | Katz et al. | Jul 2005 | A1 |
| 20050186120 | Dorian et al. | Aug 2005 | A1 |
| 20050196393 | Shanbrom | Sep 2005 | A1 |
| 20050196874 | Dorian et al. | Sep 2005 | A1 |
| 20050197293 | Mellis et al. | Sep 2005 | A1 |
| 20050247715 | Ellsworth et al. | Nov 2005 | A1 |
| 20050260174 | Fraser et al. | Nov 2005 | A1 |
| 20050260175 | Hedrick et al. | Nov 2005 | A1 |
| 20050282275 | Katz et al. | Dec 2005 | A1 |
| 20060046960 | McKay et al. | Mar 2006 | A1 |
| 20060051865 | Higgins et al. | Mar 2006 | A1 |
| 20060057223 | DiMauro et al. | Mar 2006 | A1 |
| 20060057693 | Simon | Mar 2006 | A1 |
| 20060083720 | Fraser et al. | Apr 2006 | A1 |
| 20060121002 | Rolland et al. | Jun 2006 | A1 |
| 20060140923 | Evangelista | Jun 2006 | A1 |
| 20060151384 | Ellsworth et al. | Jul 2006 | A1 |
| 20060171948 | Weinstein et al. | Aug 2006 | A1 |
| 20060175242 | Dorian et al. | Aug 2006 | A1 |
| 20060175244 | Dorian et al. | Aug 2006 | A1 |
| 20060175268 | Dorian et al. | Aug 2006 | A1 |
| 20060178610 | Nowakowski | Aug 2006 | A1 |
| 20060196885 | Leach et al. | Sep 2006 | A1 |
| 20060243676 | Swift et al. | Nov 2006 | A1 |
| 20060263407 | Mishra | Nov 2006 | A1 |
| 20060273049 | Leach et al. | Dec 2006 | A1 |
| 20060273050 | Higgins et al. | Dec 2006 | A1 |
| 20060278588 | Woodell-May | Dec 2006 | A1 |
| 20070027082 | Hasty et al. | Feb 2007 | A1 |
| 20070034579 | Dorian et al. | Feb 2007 | A1 |
| 20070036768 | Fraser et al. | Feb 2007 | A1 |
| 20070075016 | Leach | Apr 2007 | A1 |
| 20070092494 | Higgins et al. | Apr 2007 | A1 |
| 20070207161 | Ralph | Sep 2007 | A1 |
| 20070208321 | Leach et al. | Sep 2007 | A1 |
| 20080011684 | Dorian et al. | Jan 2008 | A1 |
| 20080019964 | Olmarker et al. | Jan 2008 | A1 |
| 20080064626 | Zanella | Mar 2008 | A1 |
| 20080145834 | Ho | Jun 2008 | A1 |
| 20080164204 | Hatamian et al. | Jul 2008 | A1 |
| 20080173593 | Coull et al. | Jul 2008 | A1 |
| 20080193424 | McKale et al. | Aug 2008 | A1 |
| 20080217263 | Higgins et al. | Sep 2008 | A1 |
| 20080217264 | Leach et al. | Sep 2008 | A1 |
| 20080217265 | Leach et al. | Sep 2008 | A1 |
| 20080268064 | Woodell-May | Oct 2008 | A1 |
| 20080269762 | Simon et al. | Oct 2008 | A1 |
| 20080283474 | Leach et al. | Nov 2008 | A1 |
| 20080306431 | Yoo | Dec 2008 | A1 |
| 20080318317 | Roche et al. | Dec 2008 | A1 |
| 20090014391 | Leach et al. | Jan 2009 | A1 |
| 20090018313 | Shanbrom | Jan 2009 | A1 |
| 20090047242 | Reinecke et al. | Feb 2009 | A1 |
| 20090101599 | Dorian et al. | Apr 2009 | A1 |
| 20090112146 | Wratten et al. | Apr 2009 | A1 |
| 20090181019 | Solinger | Jul 2009 | A1 |
| 20090191217 | de Wildt et al. | Jul 2009 | A1 |
| 20090192528 | Higgins et al. | Jul 2009 | A1 |
| 20090220482 | Higgins et al. | Sep 2009 | A1 |
| 20090221075 | Dorian et al. | Sep 2009 | A1 |
| 20090236297 | Dorian et al. | Sep 2009 | A1 |
| 20090250413 | Hoeppner | Oct 2009 | A1 |
| 20090253566 | Chavarria | Oct 2009 | A1 |
| 20090263319 | Wohabrebbi et al. | Oct 2009 | A1 |
| 20090289014 | Hoeppner | Nov 2009 | A1 |
| 20090317439 | Turzi et al. | Dec 2009 | A1 |
| 20100008992 | Ichim | Jan 2010 | A1 |
| 20100015129 | Abramson et al. | Jan 2010 | A1 |
| 20100055087 | Higgins et al. | Mar 2010 | A1 |
| 20100125236 | Bare et al. | May 2010 | A1 |
| 20100140182 | Chapman et al. | Jun 2010 | A1 |
| 20100186676 | Van Der | Jul 2010 | A1 |
| 20100198130 | Swift et al. | Aug 2010 | A1 |
| 20100206798 | Dorian et al. | Aug 2010 | A1 |
| 20100226909 | Hecker et al. | Sep 2010 | A1 |
| 20100256595 | Leach et al. | Oct 2010 | A1 |
| 20100323870 | Leach et al. | Dec 2010 | A1 |
| 20100324450 | Leach et al. | Dec 2010 | A1 |
| 20110014705 | Leach et al. | Jan 2011 | A1 |
| 20110020196 | Grippi et al. | Jan 2011 | A1 |
| 20110021334 | Leach et al. | Jan 2011 | A1 |
| 20110036786 | Ellsworth | Feb 2011 | A1 |
| 20110052561 | Hoeppner | Mar 2011 | A1 |
| 20110056893 | Leach et al. | Mar 2011 | A1 |
| 20110059082 | Germer et al. | Mar 2011 | A1 |
| 20110059083 | Aigner et al. | Mar 2011 | A1 |
| 20110059084 | Osterroth et al. | Mar 2011 | A1 |
| 20110065183 | Dorian et al. | Mar 2011 | A1 |
| 20110077596 | Higgins et al. | Mar 2011 | A1 |
| 20110129441 | Lentz | Jun 2011 | A1 |
| 20110168193 | Leach et al. | Jul 2011 | A1 |
| 20110189172 | Solinger et al. | Aug 2011 | A1 |
| 20110192804 | Landrigan et al. | Aug 2011 | A1 |
| 20110251041 | Chavarria et al. | Oct 2011 | A1 |
| 20110268708 | Lin et al. | Nov 2011 | A1 |
| 20120015796 | Leach et al. | Jan 2012 | A1 |
| 20120027746 | Dorian et al. | Feb 2012 | A1 |
| 20120093936 | Lindenberg et al. | Apr 2012 | A1 |
| 20120145652 | Leach et al. | Jun 2012 | A1 |
| 20120150086 | Cohen | Jun 2012 | A1 |
| 20120172836 | Higgins et al. | Jul 2012 | A1 |
| 20120228203 | Hecker et al. | Sep 2012 | A1 |
| 20130068676 | Leach et al. | Mar 2013 | A1 |
| 20130102452 | Leach et al. | Apr 2013 | A1 |
| 20130119549 | Cheng et al. | May 2013 | A1 |
| 20130178425 | Higgins et al. | Jul 2013 | A1 |
| 20130196425 | Dorian et al. | Aug 2013 | A1 |
| 20130259951 | O'Connell, Jr. | Oct 2013 | A1 |
| 20130294983 | Dorian et al. | Nov 2013 | A1 |
| 20140051061 | Landrigan et al. | Feb 2014 | A1 |
| 20140054246 | Landrigan et al. | Feb 2014 | A1 |
| 20140091048 | Leach et al. | Apr 2014 | A1 |
| 20140242045 | Higgins et al. | Aug 2014 | A1 |
| 20140271587 | Landrigan et al. | Sep 2014 | A1 |
| 20140271588 | Landrigan et al. | Sep 2014 | A1 |
| 20140271589 | Matuska et al. | Sep 2014 | A1 |
| 20140271870 | O'Shaughnessey et al. | Sep 2014 | A1 |
| 20140274893 | Woodell-May et al. | Sep 2014 | A1 |
| 20140274894 | Leach et al. | Sep 2014 | A1 |
| 20140275497 | Leach et al. | Sep 2014 | A1 |
| 20140349388 | Dorian et al. | Nov 2014 | A1 |
| 20140356446 | Leach et al. | Dec 2014 | A1 |
| 20150141332 | Toler | May 2015 | A1 |
| 20150147300 | Woodell-May et al. | May 2015 | A1 |
| Number | Date | Country |
|---|---|---|
| 696278 | Sep 1998 | AU |
| 748575 | Jun 2002 | AU |
| 9103724 | Mar 1993 | BR |
| 1321138 | Aug 1993 | CA |
| 2182862 | Jun 1996 | CA |
| 2448415 | Dec 2002 | CA |
| 1074709 | Jul 1993 | CN |
| 1321103 | Nov 2001 | CN |
| 1322146 | Nov 2001 | CN |
| 103702729 | Apr 2014 | CN |
| 105209478 | Dec 2015 | CN |
| 105338990 | Feb 2016 | CN |
| 105339007 | Feb 2016 | CN |
| 105358161 | Feb 2016 | CN |
| 105358162 | Feb 2016 | CN |
| 56103 | Oct 1960 | DE |
| 1443359 | Nov 1968 | DE |
| 4202667 | May 1993 | DE |
| 090997 | Oct 1983 | EP |
| 0102773 | Mar 1984 | EP |
| 0109374 | May 1984 | EP |
| 0142339 | May 1985 | EP |
| 0244834 | Nov 1987 | EP |
| 0253198 | Jan 1988 | EP |
| 0295771 | Dec 1988 | EP |
| 0417818 | Mar 1991 | EP |
| 0534178 | Mar 1993 | EP |
| 0592242 | Apr 1994 | EP |
| 1005910 | Jun 2000 | EP |
| 1006360 | Jun 2000 | EP |
| 1289618 | Mar 2003 | EP |
| 1427279 | Jun 2004 | EP |
| 1467746 | Oct 2004 | EP |
| 1509326 | Mar 2005 | EP |
| 1670315 | Jun 2006 | EP |
| 1716901 | Nov 2006 | EP |
| 1406492 | Dec 2009 | EP |
| 2186877 | May 2010 | EP |
| 2968412 | Jan 2016 | EP |
| 854715 | Nov 1960 | GB |
| 60053845 | Mar 1985 | JP |
| 60250014 | Dec 1985 | JP |
| 2036872 | Feb 1990 | JP |
| 02071747 | Mar 1990 | JP |
| 02129224 | May 1990 | JP |
| 2000189407 | Jul 2000 | JP |
| 2000199760 | Jul 2000 | JP |
| 2004305439 | Nov 2004 | JP |
| 2005013783 | Jan 2005 | JP |
| 2005098704 | Apr 2005 | JP |
| 2005524451 | Aug 2005 | JP |
| 2006305365 | Nov 2006 | JP |
| 2006527025 | Nov 2006 | JP |
| 2008104798 | May 2008 | JP |
| 2009155234 | Jul 2009 | JP |
| WO-8400905 | Mar 1984 | WO |
| WO-8802259 | Apr 1988 | WO |
| WO-9010031 | Sep 1990 | WO |
| WO-9108285 | Jun 1991 | WO |
| WO-9222312 | Dec 1992 | WO |
| WO-9305067 | Mar 1993 | WO |
| WO-9308904 | May 1993 | WO |
| WO-9407548 | Apr 1994 | WO |
| WO-9617871 | Jun 1996 | WO |
| WO-9848938 | Nov 1998 | WO |
| 9905989 | Feb 1999 | WO |
| 9967277 | Dec 1999 | WO |
| WO-0061256 | Oct 2000 | WO |
| WO-0074713 | Dec 2000 | WO |
| WO-0103756 | Jan 2001 | WO |
| WO-0183068 | Nov 2001 | WO |
| WO-0238610 | May 2002 | WO |
| WO-02060925 | Aug 2002 | WO |
| WO-02098566 | Dec 2002 | WO |
| WO-03015800 | Feb 2003 | WO |
| WO-03024215 | Mar 2003 | WO |
| WO-03053362 | Jul 2003 | WO |
| 03063799 | Aug 2003 | WO |
| 03080104 | Oct 2003 | WO |
| 03088905 | Oct 2003 | WO |
| WO-03092894 | Nov 2003 | WO |
| WO-03099412 | Dec 2003 | WO |
| 2004009207 | Jan 2004 | WO |
| WO-2004104553 | Dec 2004 | WO |
| WO-2005034843 | Apr 2005 | WO |
| 2006043972 | Apr 2006 | WO |
| WO-2006041406 | Apr 2006 | WO |
| 2007121538 | Nov 2007 | WO |
| 2007128973 | Nov 2007 | WO |
| WO-2007127834 | Nov 2007 | WO |
| WO 2007142908 | Dec 2007 | WO |
| 2008021237 | Feb 2008 | WO |
| WO-2008127639 | Oct 2008 | WO |
| WO-2009021257 | Feb 2009 | WO |
| WO-2009111338 | Sep 2009 | WO |
| WO-2010115190 | Oct 2010 | WO |
| WO-2011008836 | Jan 2011 | WO |
| 2011031553 | Mar 2011 | WO |
| WO-2011031524 | Mar 2011 | WO |
| WO-2011031553 | Mar 2011 | WO |
| 2012030593 | Mar 2012 | WO |
| WO-2012030593 | Mar 2012 | WO |
| WO2012030593 | Mar 2012 | WO |
| WO 2012030593 | Mar 2012 | WO |
| WO-2014144505 | Sep 2014 | WO |
| WO-2014144505 | Sep 2014 | WO |
| WO-2014149266 | Sep 2014 | WO |
| WO-2014149266 | Sep 2014 | WO |
| WO-2014149270 | Sep 2014 | WO |
| WO-2014149300 | Sep 2014 | WO |
| WO-2014149301 | Sep 2014 | WO |
| WO-2014149979 | Sep 2014 | WO |
| WO-2014150375 | Sep 2014 | WO |
| WO-2014150375 | Sep 2014 | WO |
| Entry |
|---|
| O'Shaughnessey et al. Blood-derived anti-inflammatory protein solution blocks the effect of IL-1 beta on human macrophages in vitro. Inflammation Research. Published online Jun. 18, 2011; 60(10): 929-36. |
| Vangsness et al. Stimulation of IL-1ra production from platelet-rich plasma. Poster No. 488 presented at 54th Annual Meeting of the Orthopedic Research Society, Mar. 2-5, 2008. |
| Carpenter et al. Long-term storage of proteins. Current Protocols in Protein Science. 2002; 4.6.1-4.6.6. |
| Carpenter et al. 2002. Rationale design of stable lyophilized protein formulations: theory and practice. in “Rationale Design of stable protein formulations—theory and practice” (J.F. Carpenter and M.C. Manning eds.) Kluwer Academic/Plenum publishers, New York, pp. 109-133. |
| Nakajima et al. Bioactivity of freeze-dried platelet-rich plasma in an adsorbed form on a biodegradable polymer material. Platelets 2012; 23(8):594-603). |
| Alford, J. et al. “Cartilage Restoration, Part 1” The American Journal of Sports Medicine, vol. 33, No. 2 (2005) p. 295-306. |
| Anitua, E. et al. “Autologous platelets as a source of proteins for healing and tissue regeneration” Thromb Haemost, vol. 91 (pp. 4-15) 2004. |
| Anonymous: “Update for veterinarians” Dec. 2012. vet.osu.edu/sites/default/files/documents/pdf/news/vmc/ovmaVeternarianUp/date/20121112.pdf. |
| Arend, W. et al. “Interleukin-1 Receptor Antagonist: Role in Biology” Annu. Rev. Immunol., vol. 16 (pp. 27-55) 1998. |
| Baltzer AW, et al. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage Feb. 1, 2009; 17(2):152-60. |
| Becker C. et al. Efficacy of epidural perineural injections with autologous conditioned serum for lumbar radicular compression: an Investigator-initiated, prospective, double-blind, reference-controlled study. Spine Aug. 1, 2007; 32 (17):1803-8. |
| Bendele et al. “Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis” Arthritis & Rheumatism, vol. 43, No. 12, Dec. 2000, pp. 2648-2659. |
| Bielecki, T. et al, “Antibacterial effect of autologous platelet gel enriched with growth factors and toher acive substances” J Bone Joint Surg, vol. 89-B, No. 3 (p. 417-420) Mar. 2007. |
| Bio-Rad Laboratories. Bio-Gel P Polyacrylamide Gel Instruction Manual, Obtained from www.bio-rad.com/webmaster/pdfs/9154_Bio-Gel_P.pdf on Jun. 20, 2012 (14 pages). |
| Biomet Biologics, Inc. “GPS® II Platelet Concentrate System: The New Gold Standard” Product Brochure (14 pages) Sep. 2006. |
| Biomet Biologics, Inc. “GPS® III Platelet Separation System” Product Brochure (8 pages) 2007. |
| Biomet Biologics, Inc. “Plasmax Plasma Concentrate” Product Brochure (6 pages) 2006. |
| Biomet Biologics, Inc. “Vortech Concentration System Product” Product Brochure (16 pages) Aug. 2005. |
| Biomet Biologics, Inc. “GPS System Shoulder Recovery with the GPS Platelet Concentrate System” Product Brochure (6 pages) 2004. |
| Burnouf, T. “Blood-derived, tissue engineering biomaterials” Biomedical Engineering—Applications, Basis & Communications, vol. 16, No. 6, Dec. 2004 (pp. 294-304). |
| Cell Factor Technologies, Inc. “GPS® Platelet Concentrate System” Product Brochure (9 pages) 2004. |
| Cell Factor Technologies, Inc., Biomet Europe. “GPS® II System, Gravitational Platelet Separation System” User Manual (13 pages), http://www.cellfactortech.com/global_products.cfm, printed Sep. 16, 2005. |
| Cell Factor Technologies, Inc., Biomet Europe. “GPS® II System, Gravitational Platelet Separation System, Accelerating the Body's Natural Healing Process” Product Bruchure (16 pages) 2005. |
| Dallari et al. “Enhanced Tibial Osteotomy Healing with Use of Bone Grafts Supplemented with Platelet Gel or Platelet Gel and Bone Marrow Stromal Cells” The Journal of Bone and Joint Surgery, vol. 89 (2007) pp. 2413-2420. |
| Dinarello, C. “Interleukin-1 and Interleukin-1 Antagonism” Blood, vol. 77, No. 8 (pp. 1627-1652) Apr. 1991. |
| Dinarello, C. A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood, 2011, vol. 117 (14), p. 3720-3732. |
| Eppley, et al. “Platelet Quantification and Growth Factor Analysis from Platelet-Rich Plasma: Implications for Wound Healing,” Plastic and Reconstructive Surgery, 114(6):1502-1508 (Nov. 2004). |
| Evans, C.H.Novel biological approaches to the intra-articular treatment of osteoarthritis. BioDrugs 2005; 19(6):355-62. |
| Fiotti et al. “Atherosclerosis and Inflammation. Patterns of Cytokine Regulation in Patients with Peripheral Arterial Disease” Atherosclerosis, Elsevier Ireland Ltd, IE, vol. 145, No. 1, pp. 51-60. Jul. 1, 1999. |
| Floryan, K. et al. “Home Study Program: Intraoperative use of Autologous Platelet-Rich and Platelet-Poor Plasma for Orthopedic Surgery Patients” vol. 80, No. 4 (Oct. 2004) p. 667-674. |
| Hou, WH et al. “Microfluidic Devices for Blood Fractionation” Micromachines (2011) 2, 319-343. |
| Juge-Aubry, C. et al. “Adipose Tissue is a Major Source of Interleukin-1 Receptor Antagonist” Diabetes, vol. 52, May 2003 (pp. 1104-1110). |
| Kaufman, A. et al. “Human macrophage response to UHMWPE, TiAlV, CoCr, and alumina particles: Analysis of multiple cytokines using protein arrays” Journal of Biomedical Materials Research Part A, published online in Wiley InterScience DOI: 10.1002/jbm.a.31467 (pp. 464-474) Jul. 2007. |
| Kim, Seon Hee et al. “Ex vivo gene delivery of II-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis”, Molecular Therapy, vol. 6, No. 5, Nov. 1, 2002 (pp. 591-600). |
| King, W. et al. “A simple method to Correlate the Concentration of an Anti-Inflammatory Cytokine with White Blood Cells in an Autologous Protein Solution” Feb. 24, 2014. |
| Klingenberg et al. “Treating inflammation in Atherosclerotic Cardiovascular Disease: Emerging Therapies” European Heart Journal., vol. 30, No. 23, pp. 2838-2844, Dec. 2009. |
| Lavi, G. et al. “Sustained delivery of IL-1Ra from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases” Journal of Controlled Release. 123, 123-130 (2007). |
| Lucarelli, E. et al. “Platelet-derived growth factors enhance proliferation of human stromal stem cells” Biomaterials, vol. 24 (2003) pp. 3095-3100. |
| Matthews, J. et al. “Comparison of the response of primary human peripheral blood mononuclear phagocytes from different donors to challenge with model polyethylene particles of known size and dose” Biomaterials, vol. 21 (pp. 2033-2044) 2000. |
| Meijer, H. et al. “The production of antiinflammatory cytokines in whole blood by physico-chemical induction” Inflamm. Res., vol. 52 (pp. 404-407) Oct. 2003. |
| Miltenyi Biotec GmbH, Isolation of Granulocytes From Human Peripheral Blood by Density Gradient Centrifugation (2008) 2 pages. |
| Morizaki et al. “The Effects of Platelet-Rich Plasma on Bone Marrow Stromal Cell Transplants for Tendon Healing in Vitro” J. Hand Surg. Am., vol. 35, No. 11 (Nov. 2010) pp. 1833-1841. |
| Murphy et al. “Autologous Bone Marrow Mononuclear Cell Therapy is Safe and Promotes Amputation-free Survival in Patients with Critical Limb Ischemia” Journal of Vascular Surgery, C.V. Mosby Co., vol. 53, No. 6, Jan. 28, 2011. |
| Muzio, M. et al. “Interleukin-13 Induces the Production of Interleukin-1 Receptor Antagonist (IL-1ra) and the Expression of the mRNA for the Intracellular (Keratinocyte) Form of IL-1ra in Human Myelomonocytic Cells” Blood, vol. 83, No. 7 (pp. 1738-1743) Apr. 1994. |
| Nursen Düzgün et al. “Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet's disease” Rheumatology International ; Clinical and Experimental Investigations, Springer, Berlin, DE vol. 25, No. 1, Jan. 2005. p. 1-5. |
| O'Shaughnessey, K.M. et al. Blood-derived anti-inflammatory protein solution blocks the effect of IL-1beta on human macrophages in vitro. Inflamm Res Oct. 2011; 60(10):929-36. |
| Plasmax® Plasma Concentration System. 2007. Biomet Biologics. p. 1-20. |
| Rader, C. et al.“Cytokine Response of Human Macrophage-like Cells After Contact With Polyethylene and Pure Titanium Particles” The Journal of Arthroplasty, vol. 14, No. 7 pp. 840-848 (Oct. 1999). |
| Sorbera L A “Pegsunercept. Pegylated Soluble Tumor Necrosis Factor Receptor Type 1 PEG-STNF-RI” Drugs of the Future, Prous Science, ES, vol. 28, No. 12. Jan. 1, 2003. p. 1182-1188. |
| Swift, M. et al. “Characterization of Growth Factors in Platelet Rich Plasma” Cell Factor Technologies, Inc. Printed Sep. 16, 2005 from www.cellfactortech.com/global_products.cfm. |
| Tateishi-Yuyama, E. et al. “Therapuetic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-barrow cells: a pilot study and randomised controlled trial” The Lancet 2002; 360:427-435. |
| Ulich, T.R. et al. “Intratrachael Administration of Endotoxin and Cytokines: IV. The Soluble Tumor Necrosis Factor Receptor Type 1 Inhibits Acute Inflammation” American Journal of Pathology; vol. 142, No. 5, May 1993. |
| Vangsness, T. et al. “Stimulation of IL-1ra Production from Platelet-Rich Plasma” Poster No. 488 presented at 54th Annual Meeting of the Orthopeadic Research Society in San Francisco, CA (1 page) Mar. 2-5, 2008. |
| Woodell-May, J. et al. “Effect of Incubation Time on Production of IL-1ra and sTNF-RI from Platelet-Rich Plasma” Paper No. 200, 55th Annual Meeting of the Orthopaedic Research Society (1 page) Feb. 2009. |
| Woodell-May, J. et al. “Elution of IL-1ra from a concentrated-plasma matrix—An in vitro study” Poster Presentation at 8th World Congress of the International Cartilage Repair Society, Miami, FL (1 page) May 2009. |
| Woodell-May, J. et al. “Producing Accurate Platelet Counts for Platelet Rich Plasma: Validation of a Hematology Analyzer and Preparation Techniques for Counting” Scientific Foundation, Journal of Carniofacial Surgery, vol. 16, No. 5 (pp. 749-756) Sep. 2005. |
| Woodell-May, J. et al. Autologous protein solution inhibits MMP-13 production by IL-1beta and TNFalpha-stimulated human articular chondrocytes. J Orthop Res Sep. 15, 2011; 29:1320-6. |
| Wright-Carpenter, T. “Treatment of Muscle Injuries by Local Administration of Autologous Conditioned Serum: A Pilot Study on Sportsmen with Muscle Strains” Int J Sports Med, vol. 25 (pp. 588-593) Oct. 2004. |
| Yang, S. et al. “Protective effects of IL-1Ra or vIL-10 gene transfer on a murine model of wear debris-induced osteolysis” Gene Therapy, vol. 11 (pp. 483-491) 2004. |
| Yang, T. et al. “Recent Applications of Polyacrylamide as Biomaterials” Recent Patents on Materials Science, vol. 1 (pp. 29-40) 2008. |
| Yoshida S. et al. “Elevation of serum soluble tumour necrosis factor (TNF) receptor and IL-1 receptor antagonist levels in bronchial asthma” Clinical and Experimental Immunology, Wiley-Blackwell Publishing Ltd. vol. 106, No. 1, Oct. 1996. |
| Zhang et al.“IL-1ra alleviates inflammatory hyperalgesia through preventing phosphorylation of NMDA receptor NR-1 subunit in rats” Pain. vol. 135, No. 3, Mar. 5, 2008, pp. 232-239. |
| “International Application Serial No. PCT/US2014/016900, International Search Report dated May 12, 2014”, 5 pgs. |
| “International Application Serial No. PCT/US2014/016900, Written Opinion dated May 12, 2014”. |
| “A phase I safety study of combination treatment with pegylated soluble tumor necrosis factor receptor type I (PET STNF-RI) and anakinra (interleukin-1 receptor antagonist, IL-1RA) in patients with rheumatoid arthritis”, Prous integrity, (Jun. 12, 2002), 1-1. |
| “U.S. Appl. No. 12/101,586, Final Office Action dated Feb. 3, 2011”, 11 pgs. |
| “U.S. Appl. No. 12/101,586, Non Final Office Action dated Sep. 20, 2010”, 12 pgs. |
| “U.S. Appl. No. 12/101,586, Notice of Allowance dated Mar. 24, 2011”, 5 pgs. |
| “U.S. Appl. No. 12/101,594, Final Office Action dated Mar. 18, 2010”, 8 pgs. |
| “U.S. Appl. No. 12/101,594, Non Final Office Action dated Oct. 16, 2009”, 8 pgs. |
| “U.S. Appl. No. 12/101,594, Notice of Allowance dated May 27, 2010”, 7 pgs. |
| “U.S. Appl. No. 12/897,401, Non Final Office Action dated Nov. 16, 2010”, 9 pgs. |
| “U.S. Appl. No. 12/897,401, Notice of Allowance dated Oct. 18, 2011”, 6 pgs. |
| “U.S. Appl. No. 13/837,005, Final Office Action dated Dec. 5, 2014”, 9 pgs. |
| “U.S. Appl. No. 13/837,005, Non Final Office Action dated Feb. 17, 2016”, 13 pgs. |
| “U.S. Appl. No. 13/837,005, Non Final Office Action dated May 13, 2014”, 10 pgs. |
| “U.S. Appl. No. 13/837,005, Non Final Office Action dated Jun. 9, 2015”, 13 pgs. |
| “U.S. Appl. No. 13/837,005, Response filed Jan. 3, 2014 to Restriction Requirement dated Dec. 3, 2013”, 4 pgs. |
| “U.S. Appl. No. 13/837,005, Response filed Mar. 5, 2015 to Final Office Action dated Dec. 5, 2014”, 11 pgs. |
| “U.S. Appl. No. 13/837,005, Response filed Aug. 13, 2014 to Non Final Office Action dated May 13, 2014”, 13 pgs. |
| “U.S. Appl. No. 13/837,005, Response filed Nov. 9, 2015 to Non Final Office Action dated Jun. 9, 2015”, 11 pgs. |
| “U.S. Appl. No. 13/837,005, Restriction Requirement dated Dec. 3, 2013”, 9 pgs. |
| “U.S. Appl. No. 13/837,480, Non Final Office Action dated Aug. 11, 2015”, 10 pgs. |
| “U.S. Appl. No. 13/837,480, Response filed Jan. 11, 2016 to Non Final Office Action dated Aug. 11, 2015”, 14 pgs. |
| “U.S. Appl. No. 13/837,480, Response filed Nov. 5, 2014 to Restriction Requirement dated Sep. 16, 2014”, 3 pgs. |
| “U.S. Appl. No. 13/837,480, Restriction Requirement dated Sep. 16, 2014”, 6 pgs. |
| “U.S. Appl. No. 13/839,280, Final Office Action dated Apr. 10, 2015”, 17 pgs. |
| “U.S. Appl. No. 13/839,280, Non Final Office Action dated Apr. 7, 2016”, 16 pgs. |
| “U.S. Appl. No. 13/839,280, Non Final Office Action dated Jul. 17, 2014”, 12 pgs. |
| “U.S. Appl. No. 13/839,280, Response filed Mar. 17, 2014 to Restriction Requirement dated Jan. 15, 2014”, 5 pgs. |
| “U.S. Appl. No. 13/839,280, Response filed Oct. 12, 2015 to Final Office Action dated Apr. 10, 2015”, 9 pgs. |
| “U.S. Appl. No. 13/839,280, Response filed Oct. 17, 2014 to Non Final Office Action dated Jul. 17, 2014”, 19 pgs. |
| “U.S. Appl. No. 13/839,280, Restriction Requirement dated Jan. 15, 2014”, 6 pgs. |
| “U.S. Appl. No. 13/840,129, Final Office Action dated Jun. 18, 2015”, 9 pgs. |
| “U.S. Appl. No. 13/840,129, Non Final Office Action dated Oct. 23, 2014”, 8 pgs. |
| “U.S. Appl. No. 13/840,129, Response filed Feb. 23, 2015 to Non Final Office Action dated Oct. 23, 2014”, 15 pgs. |
| “U.S. Appl. No. 13/840,129, Restriction Requirement dated Mar. 14, 2014”, 6 pgs. |
| “U.S. Appl. No. 13/841,083, Examiner Summary Received Jan. 29, 2016”, 1 pg. |
| “U.S. Appl. No. 13/841,083, Final Office Action dated Sep. 9, 2016”, 10 pgs. |
| “U.S. Appl. No. 13/841,083, Non Final Office Action dated Jan. 29, 2016”, 11 pgs. |
| “U.S. Appl. No. 13/841,083, Non Final Office Action dated Jul. 15, 2015”, 8 pgs. |
| “U.S. Appl. No. 13/841,083, Non Final Office Action dated Dec. 10, 2014”, 12 pgs. |
| “U.S. Appl. No. 13/841,083, Response filed Apr. 10, 2015 to Non Final Office Action dated Dec. 10, 2014”, 17 pgs. |
| “U.S. Appl. No. 13/841,083, Response filed Apr. 28, 2016 to Non Final Office Action dated Jan. 29, 2016”, 11 pgs. |
| “U.S. Appl. No. 13/841,083, Response filed Aug. 27, 2014 to Restriction Requirement dated Jul. 21, 2014”, 3 pgs. |
| “U.S. Appl. No. 13/841,083, Response filed Oct. 13, 2015 to Non Final Office Action dated Jul. 15, 2015”, 10 pgs. |
| “U.S. Appl. No. 13/841,083, Response filed Nov. 29, 2016 to Final Office Action dated Sep. 9, 2016”, 12 pgs. |
| “U.S. Appl. No. 13/841,083, Restriction Requirement dated Jul. 21, 2014”, 6 pgs. |
| “U.S. Appl. No. 13/841,103, Final Office Action dated Aug. 13, 2015”, 13 pgs. |
| “U.S. Appl. No. 13/841,103, Non Final Office Action dated Dec. 4, 2014”, 10 pgs. |
| “U.S. Appl. No. 13/841,103, Response filed Jan. 13, 2016 to Final Office Action dated Aug. 13, 2015”, 11 pg. |
| “U.S. Appl. No. 13/841,103, Response filed Apr. 18, 2016 to Restriction Requirement dated Feb. 19, 2016”, 8 pgs. |
| “U.S. Appl. No. 13/841,103, Response filed May 4, 2015 to Non Final Office Action dated Dec. 4, 2014”, 18 pgs. |
| “U.S. Appl. No. 13/841,103, Response filed Aug. 27, 2014 to Restriction Requirement dated Jul. 21, 2014”, 3 pgs. |
| “U.S. Appl. No. 13/841,103, Restriction Requirement dated Feb. 19, 2016”, 7 pgs. |
| “U.S. Appl. No. 13/841,103, Restriction Requirement dated Jul. 21, 2014”, 6 pgs. |
| “U.S. Appl. No. 14/050,950, Final Office Action dated Jun. 17, 2016”, 9 pgs. |
| “U.S. Appl. No. 14/050,950, Non Final Office Action dated Nov. 19, 2015”, 13 pgs. |
| “U.S. Appl. No. 14/050,950, Notice of Allowance dated Oct. 6, 2016”, 12 pgs. |
| “U.S. Appl. No. 14/050,950, Response filed Feb. 19, 2016 to Non Final Office Action dated Nov. 19, 2015”, 11 pgs. |
| “U.S. Appl. No. 14/050,950, Response filed Jun. 23, 2015 to Restriction Requirement dated Apr. 23, 2015”, 1 pgs. |
| “U.S. Appl. No. 14/050,950, Response filed Aug. 17, 2016 to Final Office Action dated Jun. 17, 2016”, 8 pgs. |
| “U.S. Appl. No. 14/050,950, Restriction Requirement dated Apr. 23, 2015”, 7 pgs. |
| “U.S. Appl. No. 14/841,086, Examiners Interview Summary dated Nov. 7, 2016”, 3 pgs. |
| “U.S. Appl. No. 14/973,913, Preliminary Amendment filed Mar. 2, 2016”, 10 pgs. |
| “U.S. Appl. No. 13/840,129, Response filed May 14, 2014 to Restriction Requirement dated Mar. 14, 2014”, 3 pgs. |
| “Arthritis”, [Online]. Retrieved from the Internet: Wayback Machine <URL:http://www.mayoclinic.org/diseases-conditions/arthritis/basics/treatment/con-20034095 >, (2014), 5 pgs. |
| “Bio-Rad Laboratories. Bio-Gel P Polyacrylamide Gel Instruction Manual”, [Online]. Retrieved from the Internet: <www.bio-rad.com/webmaster/pdfs/9154 Bio-Gel P.pdf>, (Jun. 20, 2012), 14 pgs. |
| “BioCUE™ Platelet Concentration System”, (Jun. 2010), 2 pgs. |
| “Canadian Application Serial No. 2,905,552, Voluntary Amendment filed Sep. 11, 2015”. |
| “Canadian Application Serial No. 2,906,310, Voluntary Amendment filed Sep. 14, 2015”, 2 pgs. |
| “Caps for Corning® and Costar®, Plastic Labware”, Technical Bulletin, (Dec. 2008), 2 pgs. |
| “Cell Isolation Techniques, Methods and Materials, Working with Enzymes”, Worthington Biochemical Corp, (2004), 9 pgs. |
| “Cell Isolation Theory, Tissue Types”, Worthington Biochemical Corp, (2004), 5 pgs. |
| “Centrifuge Tubes”, Corning Costar, (1996/1997), 76-77. |
| “Chinese Application Serial No. 201080019707.7, Office Action dated Jun. 30, 2014”, in English, 7 pgs. |
| “Chinese Application Serial No. 201280030026.X, Office Action dated Nov. 21, 2014”, w/ English Translation, 27 pgs. |
| “Chinese Application Serial No. 201480027157.1, Voluntary Amendment filed Jun. 6, 2016”, w/English Claims, 63 pgs. |
| “Clotalyst® Autologous Clotting Factor”, “Would you like to have an autologous thrombin for rapid clotting and haemostasis?” Biomet Biologics, (Jan. 2007), 16 pgs. |
| “Corning® 15 and 50 ml Centrifuge Tubes”, Life Sciences. Corning Incorporated., (Jun. 2005), 2 pgs. |
| “Cytori Celution Cell Concentrate Device”, Exhibit 14, 501(k) Summary, FDA approval K060482, (Sep. 28, 2006), 7 pgs. |
| “European Application Serial No. 10712677.3, Examination Notification Art. 94(3) dated Jun. 5, 2013”, 5 pgs. |
| “European Application Serial No. 14709014.6, Office Action dated Nov. 19, 2015”, 2 pgs. |
| “European Application Serial No. 14709803.2, Communication Pursuant to Article 94(3) EPC dated Jul. 8, 2016”, 7 pgs. |
| “European Application Serial No. 14709803.2, Response filed May 16, 2016 to Communication pursuant to Rules 161(1) and 162 EPC dated Nov. 5, 2015”, 14 pgs. |
| “European Application Serial No. 14709803.2, Response filed Nov. 15, 2016 to Communication Pursuant to Article 94(3) EPC dated Jul. 8, 2016”, 18 pgs. |
| “European Application Serial No. 14724817.3, Office Action dated Oct. 27, 2015”, 2 pgs. |
| “Fibrostik™ Plasma Concentrator”, Attention Operating Surgeon, Cell Factor Technologies, Inc., (Jul. 2003), 2 pgs. |
| “Frequently Asked Questions, 1. Kits, 2. Enzymes”, Worthington Biochemical Corp, (2003), 3 pgs. |
| “GPS® III Platelet Separation System, Leadership through Technology”, Biomet Biologics, Inc, (Jul. 2007), 8 pgs. |
| “Hemocor HPH® Hemoconcentrator”, Minntech® Filtration Technologies Group, Minntech Corporation (2004), <http://www.minntech.com/ftg/products/hph/index.html>, (Jul. 15, 2004), 2 pgs. |
| “Increasing bone graft bioactivity through reproducible concentrations of natural growth factors”, Symphony II Platelet Concentrate System/PCS brochure, (Jan. 2003), 8 pgs. |
| “International Application Serial No. PCT/US2003/016506, International Search Report dated Oct. 13, 2003”, 2 pgs. |
| “International Application Serial No. PCT/US2007/012587, International Search Report dated Nov. 6, 2007”, 2 pgs. |
| “International Application Serial No. PCT/US2008/004687, International Preliminary Report on Patentability dated Aug. 13, 2009”, 19 pgs. |
| “International Application Serial No. PCT/US2008/004687, International Search Report dated Jul. 2, 2008”, 3 pgs. |
| “International Application Serial No. PCT/US2008/004687, Written Opinion dated Mar. 17, 2009”, 5 pgs. |
| “International Application Serial No. PCT/US2008/004687, Written Opinion dated Jul. 2, 2008”, 5 pgs. |
| “International Application Serial No. PCT/US2009/035564, International Preliminary Examination Report dated Aug. 31, 2010”, 6 pgs. |
| “International Application Serial No. PCT/US2009/035564, International Search Report dated Jul. 3, 2009”, 3 pgs. |
| “International Application Serial No. PCT/US2009/035564, Written Opinion dated Jul. 3, 2009”, 5 pgs. |
| “International Application Serial No. PCT/US2010/029957, International Preliminary Report on Patentability dated Oct. 13, 2011”, 10 pgs. |
| “International Application Serial No. PCT/US2010/029957, International Search Report dated Jul. 30, 2010”, 6 pgs. |
| “International Application Serial No. PCT/US2010/029957, Written Opinion dated Jul. 30, 2010”, 9 pgs. |
| “International Application Serial No. PCT/US2010/041942, International Preliminary Report on Patentability dated Jan. 26, 2012”, 9 pgs. |
| “International Application Serial No. PCT/US2010/041942, International Search Report dated Oct. 8, 2010”, 3 pgs. |
| “International Application Serial No. PCT/US2010/041942, Written Opinion dated Oct. 8, 2010”, 8 pgs. |
| “International Application Serial No. PCT/US2011/031954, International Search Report dated Aug. 9, 2011”, 4 pgs. |
| “International Application Serial No. PCT/US2011/031954, Written Opinion dated Aug. 9, 2011”, 9 pgs. |
| “International Application Serial No. PCT/US2011/045290, International Search Report dated Nov. 7, 2011”, 5 pgs. |
| “International Application Serial No. PCT/US2011/045290, Written Opinion dated Nov. 7, 2011”, 5 pgs. |
| “International Application Serial No. PCT/US2012/034104, International Preliminary Report on Patentability dated Oct. 31, 2013”, 7 pgs. |
| “International Application Serial No. PCT/US2012/034104, International Search Report dated Oct. 29, 2012”, 5 pgs. |
| “International Application Serial No. PCT/US2012/034104, Written Opinion dated Oct. 29, 2012”, 6 pgs. |
| “International Application Serial No. PCT/US2013/056793, International Preliminary Report on Patentability dated Mar. 12, 2015”, 8 pgs. |
| “International Application Serial No. PCT/US2013/056793, International Search Report dated Dec. 5, 2013”, 3 pgs. |
| “International Application Serial No. PCT/US2013/056793, Written Opinion dated Dec. 5, 2013”, 6 pgs. |
| “International Application Serial No. PCT/US2014/016384, International Preliminary Report on Patentability dated Sep. 24, 2015”, 16 pgs. |
| “International Application Serial No. PCT/US2014/016384, International Search Report dated Oct. 9, 2014”, 10 pgs. |
| “International Application Serial No. PCT/US2014/016384, Written Opinion dated Oct. 9, 2014”, 14 pgs. |
| “International Application Serial No. PCT/US2014/016421, International Preliminary Report on Patentability dated Sep. 24, 2015”, 16 pgs. |
| “International Application Serial No. PCT/US2014/016421, International Search Report dated Jul. 24, 2014”, 8 pgs. |
| “International Application Serial No. PCT/US2014/016421, Written Opinion dated Jul. 24, 2014”, 14 pgs. |
| “International Application Serial No. PCT/US2014/016895, International Preliminary Report on Patentability dated Sep. 24, 2015”, 16 pgs. |
| “International Application Serial No. PCT/US2014/016895, International Search Report dated Jul. 24, 2014”, 9 pgs. |
| “International Application Serial No. PCT/US2014/016895, Written Opinion dated Jul. 24, 2014”, 14 pgs. |
| “International Application Serial No. PCT/US2014/021707, International Preliminary Report on Patentability dated Sep. 24, 2015”, 16 pgs. |
| “International Application Serial No. PCT/US2014/021707, International Search Report dated Sep. 24, 2014”, 8 pgs. |
| “International Application Serial No. PCT/US2014/021707, Written Opinion dated Jul. 24, 2014”, 14 pgs. |
| “International Application Serial No. PCT/US2014/023091, International Preliminary Report on Patentability dated Sep. 24, 2015”, 11 pgs. |
| “International Application Serial No. PCT/US2014/023091, International Search Report dated Oct. 9, 2014”, 7 pgs. |
| “International Application Serial No. PCT/US2014/023091, Written Opinion dated Oct. 9, 2014”, 9 pgs. |
| “International Application Serial No. PCT/US2014/028942, International Preliminary Report on Patentability dated Sep. 24, 2015”, 15 pgs. |
| “Japanese Application Serial No. 2010-503066, Office Action dated Jan. 22, 2013”, w/ English Translation, 17 pgs. |
| “Japanese Application Serial No. 2012-503768, Office Action dated May 20, 2014”, w/ English Translation, 5 pgs. |
| “Japanese Application Serial No. 2012-520742, Office Action dated Sep. 9, 2014”, w/ English Translation, 6 pgs. |
| “Japanese Application Serial No. 2014-024420, Preliminary Notice of Reasons for Rejection dated Feb. 24, 2015”, w/ English Translation, 15 pgs. |
| “Knee Cartilage Implantation Carticel™, Autologous Cultured Chondrocyte Implantation”, The Sports Medicine Center, [Online]. Retrieved from the Internet: <http://www.orthoassociates.com/carticel.htm>, (Apr. 6, 2006), 7 pgs. |
| “Letter CryoSeal FS System. Vaccines, Blood & Biologics”, FDA U.S. Food and Drug Administation., http://www.fda.gov/BiologicsBloodVaccines/BioodBioodProducts/ApprovedProducts/Premarket ApprovalsPMAs/ucm091631.htm, (Jul. 26, 2007), 21 pgs. |
| “MarrowStim™ Concentration Kit Peripheral Arterial Disease (PAD) Study”, Retriewed From Intenet : <http://www.biomet.com/patients/clinical recruitment padstudy.cfm>, (Jul. 2, 2009), 2 pgs. |
| “MarrowsTim™ Concentration System”, Biomet Biologics, Inc, (Feb. 15, 2008), 20 pgs. |
| “Medical Applications: Blood Filtration”, Minntech® Filtration Technologies Group, Minntech Corporation (2004), <http://www.minntech.com/ftg/industries/medical/blood_filter.html>, (Jul. 15, 2004), 1 pg. |
| “Minivalve international: duckbill valves—du 054.001 sd”, [Online]. Retrieved from the Internet: <http://www.minivalve.com/htm/DV054.htm>, 1 pg. |
| “Momentive Silopren*LSR 2050”, (Jun. 30, 2014), 3 pg. |
| “Platelet Rich Plasma (PRP)”, The Stone Clinic, (May 2006), 2 pgs. |
| “Prosys PRP Kit”, Tozai Holdings, Inc. EC21 Global B2B Marketplace, Retrieved From Internet : <http://www.ec21.com/product-details/Prosys-PRP-Kit--5467061.html Printed from Web>, (Jul. 18, 2011), 5 pgs. |
| “Renaflo® II Hemofilter”, Minntech® Filtration Technologies Group, Minntech Corporation (2004), <http://www.minntech.com/ftg/products/renaflo/index.html>, (Jul. 15, 2004), 2 pgs. |
| “Sigma-Aldrich® Alkaline Phosphatase (Procedure No. 85), drug fact sheet”, Sigma-Aldrich, (2003), 1-2. |
| “SmartPrep PRP-20 Procedure Pack—Instructions for Use”, Harvest, 12 pgs. |
| “ThermoGenesis Corp. to Supply Autologous Thrombin Kits to Biornet, Inc”, noblood: Transfusion Alternatives Patient Blood Mangement, [Online]. Retrieved from the Internet: <URL: http://noblood.org/forum/threads/2128-ThermoGenesis-Corp-to-Supply-Autologous-Thrombin-Kits-to-Biomet-Inc>, (Apr. 5, 2005), 3 pgs. |
| “Vernay Product Information Sheet, Umbrella Check Valve”, Part No. V251010200, (Jul. 2013), 2 pgs. |
| Andia, Isabel, et al., “Platelet-rich plasma for managing pain and inflammation in osteoarthritis”, Nature Reviews Rheumatology, vol. 9. No. 12., (Oct. 1, 2013), 721-730. |
| Badiavas, Evangelos V., et al., “Treatment of Chronic Wounds With Bone Marrow-Derived Cells”, Arch Dermatol. 139, (Apr. 2003), 510-516. |
| Bang, N U, et al. “Plasma Protein Requirements for Human Platelet Aggregation”, Acad Sci, 201, (1972), 280-299. |
| Bendele, Alison M, et al., “Combination Benefit of Treatment With the Cytokine Inhibitors Interleukin-1 Receptor Antagonist and Pegylated Soluble Tumor Necrosis Factor Receptor Type I in Animal Models of Rheumatoid Arthritis”, Arthritis & Rheumatism, J.B. Lippincott vol. 43, No. 12, (Dec. 1, 2000), 2648-2659. |
| Berguer, R, et al., “Warning: fatal reaction to the use of fibrin glue in deep hepatic wounds. Case reports”, J Trauma 31, (1991), 408-411. |
| Berruyer, M, et al., “Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors”, J Thorac Cardiovasc Sura 105, (1993), 892-7. |
| Boomgaard, et al., “Pooled Platelet Concentrates Prepared by the Platelet-Rich-Plasma Method and Filtered with Three Different Filters and Stored for 8 Days”, Vox Sanq, vol. 68, (Feb. 1995), 82-89. |
| Brodke, et al., “Bone Grafts Prepared with Selective Cell Retention Technology Heal Canine Segmental Defects as Effectively as Autograft”, SCR-Enriched Bone Grafts Heal Canine Segmental Defects, Journal of Orthopaedic Research, (May 2006), 857-866. |
| Casali, B, et al., “Fibrin glue from single-donation autologous plasmapheresis”, Transfusion 32, (1992), 641-643. |
| Clayden, J D, et al., “Improved segmentation reproducibility in group tractography using a quantitative tract similarity measure”, Neuroimage, Academic Press, Orlando, FL, US vol. 33, No. 2, (Nov. 1, 2006), 482-492. |
| Collier, B S, et al., “The pH Dependence of Quantitative Ristocetin-induced Platelet Aggregation: Theoretical and Practical Implications—A New Device for Maintenance of Platelet-Rich Plasma pH”, Hematology Service, Clinical Pathology Department, Clinical Center, National Institutes of Health, Bethesda Blood, vol. 47, No. 5, (May 1976). |
| Connolly, John, et al., “Development of an Osteogenic Bone-Marrow Preparation”, The Journal of Bone and Joint SurQery, Incorporated. vol. 71-A, No. 5, (Jun. 1989), 684-691. |
| Connolly, John F., “Injectable Bone Marrow Preparations to Stimulate Osteogenic Repair”, Clinical Orthopaedics and Related Research 313, (Apr. 1995), 8-18. |
| Dallari, et al., “In Vivo Study on the Healing of Bone Defects Treated with Bone Marrow Stromal Cells, Platelet-Rich Plasma, and Freeze-Dried Bone Allografts, Alone and in Combination”, Healing of Bone Defects, Journal of Orthopaedic Research, (May 2006), 877-888. |
| Dawson, J, et al., “Effects of soluble interleukin-1 type II receptor on rabbit antigen-induced arthritis: Clinical, biochemical and histological assessment”, Rheumatology (Oxford) vol. 38, No. 5, (May 5, 1999), 401-406. |
| De Ugarte, et al., “Comparison of Multi-Lineage Cells from Human Adipose Tissue and Bone Marrow”, Cells Tissues Organs 174, (2003), 101-109. |
| De Ugarte, et al., “Differential Expression of Stem Cell Mobilization-Associated Molecules on Multi-Lineage Cells from Adipose Tissue and Bone Marrow”, Immunology Letters 89, (2003), 267-270. |
| De Wit, et al., “Experiments on the Preparation of Blood Components with the IBM 2991 Blood Cell Processor”, Vox Sang. 29, (Feb. 10, 1975), 352-362. |
| Delrossi, A, et al., “Platelet-rich plasma reduces postoperative blood loss after cardiopulmonary bypass”, J Thorac Cardiovasc Sura 100, (Aug. 1990), 281-285. |
| Depalma, L, “The preparation of fibrinogen concentrate for use as fibrin glue by four different methods”, Transfusion vol. 33, No. 9, (1993), 717-720. |
| Deugarte, M D, et al., “Future of Fat as Raw Material for Tissue Regeneration”, Lippincott Williams & Wilkins, Inc., (2007), 215-219. |
| Dimuzio, Paul, et al., “Development of a Tissue-Engineered Bypass Graft Seeded with Stem Cells”, Vascular, vol. 14, No. 6, (2006), 338-342. |
| Dinarello, C, “Interleukin-1 and Interleukin-1 Antagonism”, Blood, vol. 77, No. 8, (Apr. 1991), 1627-1652. |
| Edlich, Richard F, et al., “Surgical Devices in Wound Healing Management”, In Wound Healing: Biochemical & Clinical Aspects 1st ed., vol. Philadelphia: W.B. Saunders Company, (1992), 581-601. |
| Ehricke, H H, et al., “Visualizing MR diffusion tensor fields by dynamic fiber tracking and uncertainty mapping”, Computers and Graphics, Elsevvier vol. 30, No. 2, (Apr. 1, 2006), 255-264. |
| Epstein, G H, et al., “A new autologous fibrinogen-based adhesive for otologic surgery”, Ann Otol Rhinol Laryngol 95, (May 25-26, 1985), 40-45. |
| Feige, U, et al., “Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats”, Cmls Cellular and Molecular Li Fe Sciences, Bi Rkhauser Verlag, Heidelberg, DE, vol. 57, No. 10, (Sep. 1, 2000), 1457-1470. |
| Fraser, John K, et al., “Plasticity of human adipose stem cells toward endothelial cells and cardiomyocytes”, Nature Clinical Practice Cardiovascular Medicine, vol. 3, Supplement 1, (Mar. 2006), S33-S37. |
| Friesen, Robert, et al., “Blood Conservation During Pediatric Cardiac Surgery: Ultrafiltration of the Extracorporeal Circuit Volume After Cardiopulmonary Bypass”, Anesth, Analg, (1993), 702-707. |
| Galois, et al., “Cartilage Tissue Engineering: State-of-the-Art and Future Approaches”, Pathol Bioi (Paris), 53—Abstract only, (Dec. 2005), 2 pgs. |
| Gerald, Marx, “Mechanism of Fibrin Coagulation Based on Selective, Cation-Driven, Protofibral Association”, Biopolymers, vol. 27, (1988), 763-774. |
| Gibble, et al., “Fibrin glue: the perfect operative sealant”, Transfusion, 1990, vol. 30, No. 8., (1990), 741-747. |
| Gimble, Jeffrey M, “Adipose-Derived Stem Cells for Regenerative Medicine”, Circulation Research American Heart Association, Inc., (May 11, 2007), 1249-1260. |
| Gomillion, Cheryl T, et al., “Stem cells and adipose tissue engineering”, Biomaterials 27, Science Direct Elsevier, (2006), 6052-6063. |
| Grove, et al., “Plasticity of Bone Marrow-Derived Stem Cells”, Stem Cells: Concise Review, (Jan. 2004), 487-500. |
| Guilak, Farshid, et al., “Adipose-derived adult stem cells for cartilage tissue engineering”, Biorheology 41, (2004), 389-399. |
| Harris, E. L.V, et al., “Protein Purification Methods—A Practical Approach”, Clarification and Extraction, (1989), 7 pgs. |
| Hartman, A. R, et al., “Autologous whole plasma fibrin gel. Intraoperative procurement”, Arch Surg 127, (Mar. 1992), 357-359. |
| Hattori, et al., “Osteogenic Potential of Human Adipose Tissue-Derived Stromal Cells as an Alternative Stem Cell Source”, Cells Tissues Organs, (2004), 2-12. |
| Haynesworth, S E, et al., “Mitogenic Stimulation of Human Mesenchymal Stem Cells by Platelet Releasate Suggests a Mechanism for Enhancement of Bone Repair by Platelet Concentrate”, 48th Annual Meeting of the Orthopaedic Research Society Poster No. 0462, (2002), 1 pg. |
| Hennis, H L, et al., “Infectious disease risks of fibrin glue [letter]”, Ophthalmic Sura 23, (Sep. 1992), 1 pg. |
| Hernigou, et al., “Percutaneous Autologous Bone-Marrow Grafting for Nonunions. Influence of the Number and Concentration of Progenitor Cells”, Journal of Bone & Joint Surgery, (Jul. 2005), 1430-1437. |
| Hiromasa, Mitsuhata, et al., “An Anaphylactic Reaction to Topical Fibrin Glue”, Anesthesiology, vol. 81, No. 4, (Oct. 1994), 1074-1077. |
| Hom, D, et al., “Promoting Healing with Recombinant Human Platelet-Derived Growth Factor-BB in a Previously Irradiated Problem Wound”, The Laryngoscope, vol. 113, (Sep. 2003), 1566-1571. |
| Hood, Andrew G. et al., “Perioperative Autologous Sequestration III: A New Physiologic Glue with Wound Healing Properties”, (Jan. 1993), 126-129. |
| Ishida, et al., “Platelet-Rich Plasma With Biodegradable Gelatin Hydrogel Promotes Rabbit Meniscal Tissue Regeneration”, 52nd Annual Meeting of the Orthopaedic Research Society Paper No. 1035, (2006), 1 pg. |
| Jackson, C M, et al., “Blood coagulation”, Annu Rev Biochem 49: 765-811, (1980), 22 pgs. |
| Jayadev, Suprya, “Trypsinization of Adherent Cells”, (Aug. 8, 1991), 1 pg. |
| Johnstone, et al., “Autologous Mesenchymal Progenitor Cells in Articular Cartilage Repair”, Clinical Orthopaedics and Related Research 367S:, (Oct. 1999), S156-S162. |
| Jones, D K, et al., “Confidence mapping in diffusion ensor magnetic resonance imaging tractography using a bootstrap approach”, Magnetic Resonance in Medicine Wiley USA, vol. 53 , No. 5, (May 2005), 1143-1149. |
| Jorgensen, et al., “Stem Cells for Repair of Cartilage and Bone: The Next Challenge in Osteoarthritis and Rheumatoid Arthritis”, Annals of Rheumatic Diseases, (Aug. 2000), 5 pgs. |
| Karpatkin, S., “Heterogeneity of Human Platelets. VI., Correlation of Platelet Function with Platelet Volume”, Blood, vol. 51, No. 2, (Feb. 1978), 307-316. |
| Kim, Seon Hee, et al., “Ex vivo gene delivery of II-1 Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis”, Molecular Therapy, vol. 6, No. 5, (Nov. 1, 2002), 591-600. |
| Kim, Sun Jin, et al., “Development of a novel sustained release formulation of recombinant human growth homrone using sodium hyaluronate microparticles”, Journal of Controlled Release, 2005, vol. 104 (2005), 323-335. |
| Kimble, Robert B, et al., “Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period”, Endocrinology, The Endocrine Society, US, vol. 136, No. 7—Abstract, (Jul. 1, 1995), 1 pg. |
| Kitazawa, R, et al., “Interleukin-1 Receptor Antagonist and Tumor Necrosis Factor Binding Protein Decrease Osteoclast Formation and Bone Resorption in Ovariectomized Mice”, Journal of Clinical Investigation, American Society for Clinical Investigation, US, vol. 94, No. 6, (Dec. 1, 1994), 2397-2406. |
| Kjaergard, H. K, et al., “A simple method of preparation of autologous fibrin glue by means of ethanol”, Surg Gynecol Obstet 175, (1992), 72-3. |
| Kjaergard, H. K, “Preparation of autologous fibrin glue from pericardial Blood”, Ann Thorac Sur 55, (1993), 543-4. |
| Kuderma, H, et al., “Die klinische Anwendung der Klebung van Nervenanastomosen mit Gerinnungssubstanzen bei der Rekonstruction verletzter peripherer Nerven”, Wein Klin Wochenschr 87—Not in English, (Aug. 15, 1975), 6 pgs. |
| Kumar, Vijay, et al., “Autologous Thrombin: Intraoperative Production From Whole Blood”, Journal of American Society of Extra-Corporeal Technology, JECT, 40, (2008), 94-98. |
| Kumar, Vijay, et al., “Stability of Human Thrombin Produced From 11 ml of Plasma Using the Thrombin Processing Device”, Journal of American Society of Extra-Corporeal Technology JECT, 37, (Mar. 2005), 390-395. |
| Kumar, Vijay, et al., “Whole Blood Thrombin: Development of a Process for Intra-Operative Production of Human Thrombin”, Journal of American Society of Extra-Corporeal Technology JECT, 39, (Jan. 1, 2007), 18-23. |
| Kyosti Laitakari, M D, et al., “Autologous and Homologous Fibrinogen Sealants: Adhesive Strength”, Laryngoscope vol. 99, (Sep. 1989), 974-976. |
| Lasher, Lisa, “My Experience with PRP”, PowerPoint presentation, <http://www.cellfactortech.com/global_products.cfm>, (Sep. 16, 2005), 35 pgs. |
| Lendeckel, Stefan, et al., “Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic calvarial defects: case report”, Journal of Cranio-Maxillofacial Surgery (2004) European Association for Cranio-Maxillofacial Surgery, (2004), 370-373. |
| Lerner, R, et al., “Current status of surgical adhesives”, J Surg Res 48, (Feb. 1990), 165-80. |
| Longas, Maria O, “An Improved Method for the Purification of Human Fibrinogen”, J. Biochem vol. 11, (1980), 559-564. |
| Lori, N F, et al., “Diffusion tensor fiber tracking of human brain connectivity: acquisition methods, reliability analysis and biological results”, NMR in Biomedicine Wiley UK, vol. 15, No. 7-8, (Nov. 2002), 493-515. |
| Lu, X, et al., “Bone Marrow Mesenchymal Stem Cells: Progress in Bone/Cartilage Defect Repair”, 19(1) Abstract, (Jan. 2002), 2 pgs. |
| Marx, Gerard, et al., “Heat Denaturation of Fibrinogen to Develop a Biomedical Matrix”, Journal of Biomedical Materials Research Part B: Applied Biomaterials, (Apr. 2007), 49-57. |
| Masri, Marwan A, et al., “Isolation of Human Fibrinogen of High Purity and in High Yield Using Polyethylene Glycol 1000”, Thromb Haemostas (Struttgart) vol. 49 (2), (1983), 116-119. |
| Matras, Helene, “Fibrin Seal: The State of the Art”, Journal of Oral Maxillofacial Surgery, vol. 43, (1985), 605-611. |
| Matras, Helene, et al., “Zur nahtlosen interfaszikularen Nerventransplantation im Tierexperiment”, Wein Med Woschtr 122:37—Not in English, (1972), 517-523. |
| Matuska, et al., “Autologous Solution Protects Bovine Cartilage Explants from IL-1a and STFa-Induced Cartilage Degradation”, Journal of Orthopaedic Research, (Jul. 16, 2013), 7 pgs. |
| Mehmet, C, et al., “Autologous Fibrin Glue From Intraoperatively Collected Platelet-Rich Plasma”, Ann Thorac Surg, vol. 53, (1992), 530-531. |
| Mehta, Sanjay, et al., “Gentamicin distribution from a collagen carrier”, Journal of Orthopaedic Research, vol. 14, No. 5—Abstract, (Sep. 1, 1996), 749-754. |
| Molnar, Amy, “Stem Cells from Muscles Can Repair Cartilage, Study Finds Genetically Engineered Muscle-Derived Stem Cells Improved Cartilage Repair in Rats”, American College of Rheumatology, (2005), 2 pgs. |
| Moretz, W., et al., “A simple autologous fibrinogen glue for otologic surgery”, Otolarvnaol Head Neck Surg 95, (Jul. 1986), 122-4. |
| Nakagami, Hironori, et al., “Novel Autologous Cell Therapy in Ischemic Limb Disease Through Growth Factor Secretion by Cultured Adipose Tissue-Derived Stromal Cells”, Angiogenesis by Adipose Tissue-Derived Cells, American Heart Association, Inc., (Dec. 2005), 2542-2547. |
| Nathan, Suresh, et al., “Cell-Based Therapy in the Repair of Osteochondral Defects: A Novel Use for Adipose Tissue”, Tissue Engineering, vol. 9, No. 4, Mary Ann Liebert, Inc., (2003), 733-744. |
| Nilsson, et al., “Bone Repair Induced by Bone Morphogenetic Protein in Ulnar Defects in Dogs”, The Journal of Bone and Joint Surgery, vol. 68 B., No. 4, (Aug. 1986), 635-642. |
| Okamoto, Y, et al., “Determination of soluble tumor necrosis factor-alpha receptor type (TNFRI) and II (TNFRII) in the urine of healthy Japanese subjects”, Journal of Immunoassay and Immunochemistry, 2011, vol. 32,. (2011), 145-155. |
| Okunishi, K, et al., “Hepatocyte Growth Factor Significantly Suppresses Collagen-Induced Arthritis in Mice”, The Journal of Immunology, vol. 179, No. 8, (Oct. 15, 2007), 15 pgs. |
| Orphardt, Charles E, “Denaturation of Proteins”, Virtual Chembook, Elmhurst College, <http://www.elmhurst.edu/chm/vchembook/568denaturation.html> (web accessed Mar. 9, 2011), (2003), 3 pgs. |
| O'Shaughnessey, Krista, et al., “Autologous Protein Solution Prepared From the Blood of Osteoarthritic Patients Contains an Enhanced Profile of Anti-Inflammatory Cytokines and Anabolic Growth Factors”, Journal of Orthopaedic Research, (Jun. 1, 2014), 1349-1355 pgs. |
| Parchment, et al., “Roles for in vitro myelotoxicity tests in preclincial drug development and clinical trial planning, Toxicology Pathology, Society of Toxicological Pathologists”, vol. 21, No. 2, (1993), 241-250. |
| Parker, Anna M, et al., “Adipose-derived stem cells for the regeneration of damaged tissues”, Expert Opinion, Cell- & Tissue-based Therapy, Expert Opin. Bioi. Ther., Informa UK Ltd, (2006), 567-578. |
| Planat-Benard, V., et al,, “Spontaneous Cardiomyocyte Differentiation From Adipose Tissue Stroma Cells”, Adipose-Derived Cell Cardiomyocyte, American Head Association, Inc., (Feb. 6, 2004), 223-229. |
| Pommer, et al., “Dielectrophoretic separation of platelets from whole blood in microfluidic channels”, Electrophoresis, (2008), 1213-1218. |
| Ponticiello, Michael S, “A Rapid Technique for the Isolation and Concentration of Stem Cells from Human Bone Marrow”, Cell Factor Technologies, Inc., (2006), 1 pg. |
| Rangappa, Sunil, et al., “Transformation of Adult Mesenchymal Stem Cells Isolated From the Fatty Tissue Into Cardiomyocytes”, Adult Stem Cells Transformed into Cardiomyoctyes, Ann Thorac Surg, (2003), 775-779. |
| Rigotti, M D, et al., “Clinical Treatment of Radiotherapy Tissue Damage by Lipoaspirate Transplant: A Healing Process Mediated by Adipose-Derived Adult Stem Cells”, Plastic and Reconstructive Surgery, Breast, PRS Journal vol. 119, No. 5, Stem Cell Therapy for Angiogenesis, (Apr. 15, 2007), 1409-1422. |
| Robert, Quigley L, et al., “Intraoperative Procurement of Autologous Fibrin Glue”, Ann Thorac Surg, vol. 56, (1993), 387-389. |
| Rubin, M. D., et al., “Clinical Treatment of Radiotherapy Tissue Damage by Lipoaspirate Transplant: A Healing Process Mediated by Adipose-Derived Adult Stem Cells”, Plastic and Reconstructive Surgery, Discussion vol. 119, No. 5, Stem Cell Therapy for Angiogenesis, (Apr. 15, 2007), 1423-1424. |
| Sadeghi, M, et al., “Strikingly higher interleukin (IL)-1a, IL-1b and soluble interleukin-1 receptor antagonist (sIL-1RA) but similar IL-2, sII-2R, IL-3, IL-4, IL-6, sII-6R, IL-10, tumour necrosis factor (TNF)-a, transforming growth factor (TGF)-B2, (cont.)”, (Title cont. “transforming growth factor (TGF)-(32 and interferon IFN-y urine Levels in healthy females compared to healthy males: protection against urinary tract injury?”) Clinical and Experimental Immunology, vol. 142, (2005), 312-317. |
| Sanal, M, et al., “Does fibrin glue cause foreign body reactions?”, Eu r J Pediatr Sura 2, (1992), 285-6. |
| Schaffler, Andreas, et al., “Concise Review: Adipose Tissue-Derived Stromal Cells-Basic and Clinical Implications for Novel Cell-Based Therapies”, Tissue-Specific Stem Cells, Stem Cells®, (Apr. 10, 2007), 12 pgs. |
| Schmidt, K G, “Labelling of Human and Rabbit Platelets with Indium-Oxine Complex”, (1979), 97-106. |
| Schmidt, K G, et al., “Preparation of Platelet Suspensions from Whole Blood in Buffer”, Scand. J. Hoemato, 23, (1979), 88-96. |
| Semple, Elisabeth, et al., “Quality of Thrombin Produced From the Patient's Own Plasma Using the TPD™, a New Thrombin-Processing Device”, Journal of American Society of Extra-Corporeal Technology, 37(2), (2005), 196-200. |
| Sevenoaks, Martin J., et al., “Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity—a common inflammatory phenotype?”, respiratory Research vol. 7:70, (2006), 1-9. |
| Siedentop, Karl H, et al., “Autologous Fibrin Tissue Adhesive”, Laryngoscope, vol. 95, (Sep. 1985), 1074-1076. |
| Siedentop, Karl H, et al., “Extended Experimental and Preliminary Surgical Findings with Autologous Fibrin Tissue Adhesive Made from Patient's Own Blood”, Laryngoscope, vol. 96, (Oct. 1986), 1062-1064. |
| Sierra, D H, “Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications”, J Biomater Appl 7, (Apr. 1993), 309-52. |
| Silver, Frederick H, et al., “Review Preparation and use of fibrin glue in surgery”, Biomaterials 16 (1995), (1995), 891-903. |
| Solchaga, Luis A., et al., “Hyaluronic Acid-Based Polymers as Cell Carriers for Tissue-Engineered Repair of Bone and Cartilage”, Journal of Orthopaedic Research, Orthopaedic Research Society, US, vol. 17, (Jan. 1, 1999), 205-213. |
| Solem, Jan Otto, et al., “Hemoconcentration by Ultrafiltration During Open-Heart Surgery”, Scand J Thor Cardiovasc Surg 22, (1988), 271-274. |
| Spotnitz, William D, et al., “Successful Use of Fibrin Glue During 2 Years of Surgery at a University Medical Center”, The American Surgeon, vol. 55,, (Mar. 1989), 166-168. |
| Sutton, Robin G, et al., “Comparison of Three Blood-Processing Techniques During and After Cardiopulmonary Bypass”, Ann Thorac Surg (1993) vol. 56, (1993), 6 pgs. |
| Takahashi, Kazutoshi, et al., “Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors”, Cell, Elsevier Inc., (Nov. 30, 2007), 1-12. |
| Tawes, Jr., Roy L, et al., “Autologous Fibrin Glue: The Last Step in Operative Hemostatis”, The American Journal of Surgery, vol. 168, (Aug. 1994), 120-122. |
| Thompson, et al., “Fibrin Glue: A Review of Its Preparation, Efficacy, and Adverse Effects as a Topical Hemostat”, Drug Intelligence and Clinical Pharmacy, vol. 22, (Dec. 1988), 946-952. |
| Toriumi, Dean M, et al., “Surgical Tissue Adhesives in Otolaryngology—Head and Neck Surgery”, Otolaryngologic Clinics of North America, vol. 27, No. 1, (Feb. 1994), 203-209. |
| Wang, “Cell separation by dielectrophoretic field-flow-fractionation”, Analytical Chemistry, (2000), 832-839. |
| Weis-Fogh, U S, “Fibrinogen prepared from small blood samples for autologous use in a tissue adhesive system”, Eur Surg Res 20, (1988), 381-9. |
| Weisman, M D, “Biochemical Characterization of Autologous Fibrinogen Adhesive”, Laryngoscope 97, (Oct. 1987), 1186-1190. |
| Wiseman, David M, et al., “Wound Dressings: Design and Use”, In Wound Healing: Biochemical & Clinical Aspects 1st ed., vol., (1992), 562-580. |
| Yoon, Eulsik, et al., “In Vivo Osteogenic Potential of Human Adipose-Derived Stem Cells/Poly Lactide-Co-Glycolic Acid Constructs for Bone Regneration in a Rat Critical-Sized Calvarial Defect Model”, Tissue Engineering, vol. 13, No. 3, (2007), 619-627. |
| Zhang, Duan-Zhen, et al., “Transplantation of autologous adipose-derived stem cells ameliorates cardiac function in rabbits with myocardial infarction”, Chinese Medical Journal, vol. 120, No. 4 General Hospital of Shenyang Military Region, (2007), 300-307. |
| Zuk, P. A, et al., “Multilineage cells from human adipose tissue: Implications for cellbased therapies”, Tissue Engineering, 7(2), XP00219871 0, ISSN: 1076-3279, (Apr. 1, 2001), 211-228. |
| “International Application Serial No. PCT/US2014/016900, International Preliminary Report on Patentability dated Sep. 24, 2015”, 9 pgs. |
| “U.S. Appl. No. 13/841,083, Examiner Interview dated Feb. 24, 2017”, 1 pg. |
| “U.S. Appl. No. 13/841,083, Non Final Office Action dated Feb. 24, 2017”, 12 pgs. |
| “U.S. Appl. No. 13/841,083, Non Final Office Action dated Feb. 24, 2017”, Examiner Interview Summary from Feb. 24, 2017 included, 14 pgs. |
| “U.S. Appl. No. 13/841,083, Response filed May 24, 2017 to Non Final Office Action dated Feb. 24, 2017”, 18 pgs. |
| Agu, R. U., et al., “The lung as a route for systemic delivery of therapeutic proteins and peptides”, Respir Res.; vol. 2, (2001), pp. 198-209. |
| Number | Date | Country | |
|---|---|---|---|
| 20140274895 A1 | Sep 2014 | US |
